

References

Kidney International Supplements (2012) **2**, 259–274; doi:10.1038/kisup.2012.30

REFERENCES

- Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. *Am J Nephrol* 1988; **8**: 85–89.
- Price CP, Newall RG, Boyd JC. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. *Clin Chem* 2005; **51**: 1577–1586.
- Fine DM, Ziegenbein M, Petri M *et al.* A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. *Kidney Int* 2009; **76**: 1284–1288.
- Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. *Nephrol Dial Transplant* 2005; **20**: 707–711.
- Botev R, Mallie JP, Couchoud C *et al.* Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. *Clin J Am Soc Nephrol* 2009; **4**: 899–906.
- Rovin BH, McKinley AM, Birmingham DJ. Can we personalize treatment for kidney diseases? *Clin J Am Soc Nephrol* 2009; **4**: 1670–1676.
- Upadhyay A, Earley A, Haynes SM *et al.* Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. *Ann Intern Med* 2011; **154**: 541–548.
- Agarwal A, Haddad N, Hebert LA. Progression of kidney disease: diagnosis and management. In: Molony DA, Craig JC (eds). *Evidence-based Nephrology*, 1st edn. John Wiley & Sons: Hoboken, NJ, 2008, pp 311–322.
- National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 2004; **114**(Suppl 2): 555–576.
- Wuhl E, Trivelli A, Picca S *et al.* Strict blood-pressure control and progression of renal failure in children. *N Engl J Med* 2009; **361**: 1639–1650.
- Ogi M, Yokoyama H, Tomosugi N *et al.* Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. *Am J Kidney Dis* 1994; **24**: 427–436.
- Furth SL, Arbus GS, Hogg R *et al.* Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. *J Pediatr* 2003; **142**: 145–148.
- Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? *Nat Clin Pract Nephrol* 2008; **4**: 550–559.
- McKinney PA, Feltbower RG, Brocklebank JT *et al.* Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. *Pediatr Nephrol* 2001; **16**: 1040–1044.
- A Report of the International Study of Kidney Disease in Children. Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. *Kidney Int* 1981; **20**: 765–771.
- Fakhouri F, Bocquet N, Taupin P *et al.* Steroid-sensitive nephrotic syndrome: from childhood to adulthood. *Am J Kidney Dis* 2003; **41**: 550–557.
- Koskimies O, Viiska J, Rapola J *et al.* Long-term outcome of primary nephrotic syndrome. *Arch Dis Child* 1982; **57**: 544–548.
- Tarshish P, Tobin JN, Bernstein J *et al.* Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. *J Am Soc Nephrol* 1997; **8**: 769–776.
- Arneil GC. 164 children with nephrosis. *Lancet* 1961; **2**: 1103–1110.
- Ruth EM, Kemper MJ, Leumann EP *et al.* Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. *J Pediatr* 2005; **147**: 202–207.
- Bhimma R, Coovadia HM, Adhikari M. Nephrotic syndrome in South African children: changing perspectives over 20 years. *Pediatr Nephrol* 1997; **11**: 429–434.
- Kim JS, Bellew CA, Silverstein DM *et al.* High incidence of initial and late steroid resistance in childhood nephrotic syndrome. *Kidney Int* 2005; **68**: 1275–1281.
- Arneil GC. The nephrotic syndrome. *Pediatr Clin North Am* 1971; **18**: 547–559.
- Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of 'Arbeitsgemeinschaft fur Padiatrische Nephrologie'. *Lancet* 1979; **1**: 401–403.
- Hodson EM, Knight JF, Willis NS *et al.* Corticosteroid therapy for nephrotic syndrome in children. *Cochrane Database Syst Rev* 2005: CD001533.
- Feber J, Al-Matrafi J, Farhadi E *et al.* Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? *Pediatr Nephrol* 2009; **24**: 1027–1031.
- The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. *J Pediatr* 1981; **98**: 561–564.
- Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. *Lancet* 1988; **1**: 380–383.
- Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome. A report of 'Arbeitsgemeinschaft fur Padiatrische Nephrologie'. *Eur J Pediatr* 1981; **135**: 229–237.
- Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. *J Pediatr* 1992; **120**: 721–725.
- Letavernier B, Letavernier E, Leroy S *et al.* Prediction of high-degree steroid dependency in pediatric idiopathic nephrotic syndrome. *Pediatr Nephrol* 2008; **23**: 2221–2226.
- Noer MS. Predictors of relapse in steroid-sensitive nephrotic syndrome. *Southeast Asian J Trop Med Public Health* 2005; **36**: 1313–1320.
- Lewis MA, Baildom EM, Davis N *et al.* Nephrotic syndrome: from toddlers to twenties. *Lancet* 1989; **1**: 255–259.
- Andersen RF, Thrane N, Noergaard K *et al.* Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. *Pediatr Nephrol* 2010; **25**: 1299–1304.
- Constantinescu AR, Shah HB, Foote EF *et al.* Predicting first-year relapses in children with nephrotic syndrome. *Pediatrics* 2000; **105**: 492–495.
- Abeyagunawardena AS, Trompeter RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. *Arch Dis Child* 2008; **93**: 226–228.
- Gulati A, Sinha A, Sreenivas V *et al.* Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. *Clin J Am Soc Nephrol* 2011; **6**: 63–69.
- Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. *Clin Pediatr (Phila)* 1988; **27**: 387–392.
- Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians. *Arch Dis Child* 1994; **70**: 151–157.
- Bagga A, Ali U, Banerjee S *et al.* Management of steroid sensitive nephrotic syndrome: revised guidelines. *Indian Pediatr* 2008; **45**: 203–214.
- Srivastava RN, Vasudev AS, Bagga A *et al.* Long-term, low-dose prednisolone therapy in frequently relapsing nephrotic syndrome. *Pediatr Nephrol* 1992; **6**: 247–250.
- Kyrieleis HA, Lowik MM, Pronk I *et al.* Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. *Clin J Am Soc Nephrol* 2009; **4**: 1593–1600.
- Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. *Pediatr Nephrol* 2001; **16**: 271–282.
- Niaudet P, Habib R, Tete MJ *et al.* Cyclosporin in the treatment of idiopathic nephrotic syndrome in children. *Pediatr Nephrol* 1987; **1**: 566–573.

45. Boyer O, Moulder JK, Grandin L *et al.* Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. *Pediatr Nephrol* 2008; **23**: 575–580.
46. Hino S, Takemura T, Okada M *et al.* Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. *Am J Kidney Dis* 1998; **31**: 932–939.
47. Leroy V, Baudouin V, Alberti C *et al.* Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment. *Pediatr Nephrol* 2009; **24**: 2393–2400.
48. Mowry JA, McCarthy ET. Cyclosporine in glomerular disease. *Semin Nephrol* 1996; **16**: 548–554.
49. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. *Cochrane Database Syst Rev* 2008: CD002290.
50. Kyrieleis HA, Levtschenko EN, Wetzels JF. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. *Am J Kidney Dis* 2007; **49**: 592–597.
51. Azib S, Macher MA, Kwon T *et al.* Cyclophosphamide in steroid-dependent nephrotic syndrome. *Pediatr Nephrol* 2011; **26**: 927–932.
52. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. *Arch Dis Child* 1987; **62**: 1102–1106.
53. Williams SA, Makker SP, Ingelfinger JR *et al.* Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood. *N Engl J Med* 1980; **302**: 929–933.
54. Wetzels JF. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? *Neth J Med* 2004; **62**: 347–352.
55. Miller DG. Alkylating agents and human spermatogenesis. *JAMA* 1971; **217**: 1662–1665.
56. Weiss R. Randomized double-blind placebo controlled, multi-center trial of levamisole for children with frequently relapsing/steroid dependent nephrotic syndrome (abstract). *J Am Soc Nephrol* 1993; **4**: 289.
57. Fu LS, Shien CY, Chi CS. Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: comparison of daily and every-other-day usage. *Nephron Clin Pract* 2004; **97**: c137–c141.
58. Hafeez F, Ahmed TM, Samina U. Levamisole in steroid dependent and frequently relapsing nephrotic syndrome. *J Coll Physicians Surg Pak* 2006; **16**: 35–37.
59. Kemper MJ, Amon O, Timmermann K *et al.* [The treatment with levamisole of frequently recurring steroid-sensitive idiopathic nephrotic syndrome in children]. *Dtsch Med Wochenschr* 1998; **123**: 239–243.
60. Palcoux JB, Niaudet P, Goumy P. Side effects of levamisole in children with nephrosis. *Pediatr Nephrol* 1994; **8**: 263–264.
61. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. *Pediatr Nephrol* 1992; **6**: 1–3.
62. Ponticelli C, Edefonti A, Ghio L *et al.* Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. *Nephrol Dial Transplant* 1993; **8**: 1326–1332.
63. Yoshioka K, Ohashi Y, Sakai T *et al.* A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. *Kidney Int* 2000; **58**: 317–324.
64. El-Husseini A, El-Basuony F, Mahmoud I *et al.* Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. *Nephrol Dial Transplant* 2005; **20**: 2433–2438.
65. Hulton SA, Neuhaus TJ, Dillon MJ *et al.* Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood. *Pediatr Nephrol* 1994; **8**: 401–403.
66. Niaudet P, Broyer M, Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. *Clin Nephrol* 1991; **35**(Suppl 1): S31–S36.
67. Ishikura K, Ikeda M, Hattori S *et al.* Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. *Kidney Int* 2008; **73**: 1167–1173.
68. Filler G. How should microemulsified Cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored? *Nephrol Dial Transplant* 2005; **20**: 1032–1034.
69. Sinha MD, MacLeod R, Rigby E *et al.* Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. *Nephrol Dial Transplant* 2006; **21**: 1848–1854.
70. Dotsch J, Dittrich K, Plank C *et al.* Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? *Nephrol Dial Transplant* 2006; **21**: 1761–1763.
71. Iijima K, Hamahira K, Tanaka R *et al.* Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. *Kidney Int* 2002; **61**: 1801–1805.
72. Kranz B, Vester U, Buscher R *et al.* Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. *Pediatr Nephrol* 2008; **23**: 581–586.
73. El-Husseini A, El-Basuony F, Mahmoud I *et al.* Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome. *Eur J Clin Pharmacol* 2006; **62**: 3–8.
74. Dorresteyn EM, Kist-van Holthe JE, Levtschenko EN *et al.* Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. *Pediatr Nephrol* 2008; **23**: 2013–2020.
75. Hogg RJ, Fitzgibbons L, Bruck J *et al.* Clinical trial of mycophenolate mofetil (MMF) for frequent relapsing nephrotic syndrome in children (abstract). *Pediatr Nephrol* 2004; **19**: C66.
76. Afzal K, Bagga A, Menon S *et al.* Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. *Pediatr Nephrol* 2007; **22**: 2059–2065.
77. Barletta GM, Smoyer WE, Bunchman TE *et al.* Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. *Pediatr Nephrol* 2003; **18**: 833–837.
78. Ettenger R, Bartosh S, Choi L *et al.* Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. *Pediatr Transplant* 2005; **9**: 780–787.
79. Ravani P, Magnasco A, Edefonti A *et al.* Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. *Clin J Am Soc Nephrol* 2011; **6**: 1308–1315.
80. Guignon V, Dallochio A, Baudouin V *et al.* Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. *Pediatr Nephrol* 2008; **23**: 1269–1279.
81. Prytula A, Iijima K, Kamei K *et al.* Rituximab in refractory nephrotic syndrome. *Pediatr Nephrol* 2010; **25**: 461–468.
82. Chaumais MC, Garnier A, Chalard F *et al.* Fatal pulmonary fibrosis after rituximab administration. *Pediatr Nephrol* 2009; **24**: 1753–1755.
83. Gulati S, Sharma AP, Sharma RK *et al.* Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? *Pediatr Nephrol* 2002; **17**: 404–408.
84. Gulati S, Sural S, Sharma RK *et al.* Spectrum of adolescent-onset nephrotic syndrome in Indian children. *Pediatr Nephrol* 2001; **16**: 1045–1048.
85. Baqi N, Singh A, Balachandra S *et al.* The paucity of minimal change disease in adolescents with primary nephrotic syndrome. *Pediatr Nephrol* 1998; **12**: 105–107.
86. Gipson DS, Chin H, Presler TP *et al.* Differential risk of remission and ESRD in childhood FSGS. *Pediatr Nephrol* 2006; **21**: 344–349.
87. Gorensk MJ, Lebel MH, Nelson JD. Peritonitis in children with nephrotic syndrome. *Pediatrics* 1988; **81**: 849–856.
88. Ulinski T, Leroy S, Dubrel M *et al.* High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. *Pediatr Nephrol* 2008; **23**: 1107–1113.
89. Aoun B, Wannous H, Azema C *et al.* Polysaccharide pneumococcal vaccination of nephrotic children at disease onset-long-term data. *Pediatr Nephrol* 2010; **25**: 1773–1774.
90. The Australian immunisation handbook. Australian Government Department of Health and Ageing, Office of Health Protection: Woden, ACT, 2008.
91. American Academy of Pediatrics. Section 1: Active and passive immunization. In: Pickering LK, Baker CJ, Long SS, McMillan JA (eds). *Red Book: 2006 Report of the Committee on Infectious Diseases*, 27th edn. Elk Grove Village, IL, 2006, pp 1–103.
92. Trachtman H, Fine R, Friedman A *et al.* Quality of life in children with focal segmental glomerulosclerosis: baseline findings. Report of the FSGS clinical trial (CT) (abstract). *J Am Soc Nephrol* 2009; **20**: 147A.
93. Kerlin BA, Blatt NB, Fuh B *et al.* Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. *J Pediatr* 2009; **155**: 105–110, 110 e101.
94. Soeiro EM, Koch VH, Fujimura MD *et al.* Influence of nephrotic state on the infectious profile in childhood idiopathic nephrotic syndrome. *Rev Hosp Clin Fac Med Sao Paulo* 2004; **59**: 273–278.
95. Uncu N, Bulbul M, Yildiz N *et al.* Primary peritonitis in children with nephrotic syndrome: results of a 5-year multicenter study. *Eur J Pediatr* 2010; **169**: 73–76.

96. USRDS 2003. *Annual data report: Atlas of end-stage renal disease in the United States*. US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2003.
97. Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. *Lancet* 1974; **2**: 423-427.
98. Tarshish P, Tobin JN, Bernstein J *et al*. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. *Pediatr Nephrol* 1996; **10**: 590-593.
99. Gipson DS, Massengill SF, Yao L *et al*. Management of childhood onset nephrotic syndrome. *Pediatrics* 2009; **124**: 747-757.
100. Abrantes MM, Cardoso LS, Lima EM *et al*. Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis. *Pediatr Nephrol* 2006; **21**: 1003-1012.
101. Chitalia VC, Wells JE, Robson RA *et al*. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. *Kidney Int* 1999; **56**: 2236-2242.
102. Cosio FG, Hernandez RA. Favorable prognostic significance of raised serum C3 concentration in patients with idiopathic focal glomerulosclerosis. *Clin Nephrol* 1996; **45**: 146-152.
103. Troyanov S, Wall CA, Miller JA *et al*. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. *J Am Soc Nephrol* 2005; **16**: 1061-1068.
104. Hogg RJ, Furth S, Lemley KV *et al*. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. *Pediatrics* 2003; **111**: 1416-1421.
105. Chernin G, Heeringa SF, Gbadegesin R *et al*. Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. *Pediatr Nephrol* 2008; **23**: 1455-1460.
106. Karle SM, Uetz B, Ronner V *et al*. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. *J Am Soc Nephrol* 2002; **13**: 388-393.
107. Faul C, Donnelly M, Merscher-Gomez S *et al*. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. *Nat Med* 2008; **14**: 931-938.
108. Garin EH, Orak JK, Hiott KL *et al*. Cyclosporine therapy for steroid-resistant nephrotic syndrome. A controlled study. *Am J Dis Child* 1988; **142**: 985-988.
109. Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. *J Am Soc Nephrol* 1996; **7**: 56-63.
110. Ponticelli C, Rizzoni G, Edefonti A *et al*. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. *Kidney Int* 1993; **43**: 1377-1384.
111. Gipson DS, Trachtman H, Kaskel FJ *et al*. Clinical trial of focal segmental glomerulosclerosis in children and young adults. *Kidney Int* 2011; **80**: 868-878.
112. Caridi G, Perfumo F, Ghiggeri GM. NPHS2 (Podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. *Pediatr Res* 2005; **57**: 54R-61R.
113. Choudhry S, Bagga A, Hari P *et al*. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. *Am J Kidney Dis* 2009; **53**: 760-769.
114. Winn MP. Not all in the family: mutations of podocin in sporadic steroid-resistant nephrotic syndrome. *J Am Soc Nephrol* 2002; **13**: 577-579.
115. Bagga A, Mudigoudar BD, Hari P *et al*. Enalapril dosage in steroid-resistant nephrotic syndrome. *Pediatr Nephrol* 2004; **19**: 45-50.
116. Li Z, Duan C, He J *et al*. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. *Pediatr Nephrol* 2010; **25**: 883-888.
117. Hari P, Bagga A, Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. *Indian Pediatr* 2004; **41**: 993-1000.
118. de Mello VR, Rodrigues MT, Mastrocinque TH *et al*. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. *Pediatr Nephrol* 2010; **25**: 453-460.
119. Hodson EM, Craig JC. Therapies for steroid-resistant nephrotic syndrome. *Pediatr Nephrol* 2008; **23**: 1391-1394.
120. Plank C, Kalb V, Hinkes B *et al*. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome—a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. *Pediatr Nephrol* 2008; **23**: 1483-1493.
121. Nachman PH, Jennette JC, Falk RJ. Primary glomerular diseases. In: Brenner BM (ed). *Brenner and Rector's The Kidney*, 8th edn. Saunders/Elsevier: Philadelphia, PA, 2008, pp 987-1066.
122. Arneil GC, Lam CN. Long-term assessment of steroid therapy in childhood nephrosis. *Lancet* 1966; **2**: 819-821.
123. Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. *Br Med J* 1970; **3**: 421-426.
124. Coggins CH. Adult minimal change nephropathy: experience of the collaborative study of glomerular disease. *Trans Am Clin Climatol Assoc* 1986; **97**: 18-26.
125. Huang JJ, Hsu SC, Chen FF *et al*. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. *Am J Nephrol* 2001; **21**: 28-34.
126. Radhakrishnan J, Appel AS, Valeri A *et al*. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. *Am J Kidney Dis* 1993; **22**: 135-142.
127. McIntyre P, Craig JC. Prevention of serious bacterial infection in children with nephrotic syndrome. *J Paediatr Child Health* 1998; **34**: 314-317.
128. Mahmoodi BK, ten Kate MK, Waanders F *et al*. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. *Circulation* 2008; **117**: 224-230.
129. Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. *Nephrol Dial Transplant* 1996; **11**: 2192-2201.
130. Waldman M, Crew RJ, Valeri A *et al*. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. *Clin J Am Soc Nephrol* 2007; **2**: 445-453.
131. Korbet SM, Schwartz MM, Lewis EJ. Minimal-change glomerulopathy of adulthood. *Am J Nephrol* 1988; **8**: 291-297.
132. Nolasco F, Cameron JS, Heywood EF *et al*. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. *Kidney Int* 1986; **29**: 1215-1223.
133. Tse KC, Lam MF, Yip PS *et al*. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. *Nephrol Dial Transplant* 2003; **18**: 1316-1320.
134. Appel GB, Radhakrishnan J, d'Agati V. Secondary glomerular diseases. In: Brenner BM (ed). *Brenner and Rector's The Kidney*, 8th edn. Saunders/Elsevier: Philadelphia, PA, 2008, pp 1067-1146.
135. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. *Cochrane Database Syst Rev* 2007: CD001533.
136. Palmer SC, Nand K, Strippoli GF. Interventions for minimal change disease in adults with nephrotic syndrome. *Cochrane Database Syst Rev* 2008: CD001537.
137. Al-Khader AA, Lien JW, Aber GM. Cyclophosphamide alone in the treatment of adult patients with minimal change glomerulonephritis. *Clin Nephrol* 1979; **11**: 26-30.
138. Uldall PR, Feest TG, Morley AR *et al*. Cyclophosphamide therapy in adults with minimal-change nephrotic syndrome. *Lancet* 1972; **1**: 1250-1253.
139. Matsumoto H, Nakao T, Okada T *et al*. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. *Intern Med* 2004; **43**: 668-673.
140. Li X, Li H, Chen J *et al*. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. *Nephrol Dial Transplant* 2008; **23**: 1919-1925.
141. Meyrier A, Condamine MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. *Clin Nephrol* 1991; **35**(Suppl 1): S37-S42.
142. Eguchi A, Takei T, Yoshida T *et al*. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. *Nephrol Dial Transplant* 2010; **25**: 124-129.
143. Meyrier A, Niaudet P, Brodehl J. *Optimal use of Sandimmun in Nephrotic Syndrome*. Springer: Berlin, Germany, 1993.
144. Meyrier A, Noel LH, Auriche P *et al*. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. *Kidney Int* 1994; **45**: 1446-1456.
145. Choi MJ, Eustace JA, Gimenez LF *et al*. Mycophenolate mofetil treatment for primary glomerular diseases. *Kidney Int* 2002; **61**: 1098-1114.
146. Fujinaga S, Ohtomo Y, Hirano D *et al*. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. *Clin Nephrol* 2009; **72**: 268-273.

147. Siu YP, Tong MK, Leung K *et al.* The use of enteric-coated mycophenolate sodium in the treatment of relapsing and steroid-dependent minimal change disease. *J Nephrol* 2008; **21**: 127–131.
148. Jennette JC, Falk RJ. Adult minimal change glomerulopathy with acute renal failure. *Am J Kidney Dis* 1990; **16**: 432–437.
149. Lechner BL, Bockenhauer D, Iragorri S *et al.* The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. *Pediatr Nephrol* 2004; **19**: 744–748.
150. Yalavarthy R, Smith ML, Edelstein C. Acute kidney injury complicating minimal change disease: the case for careful use of diuretics and angiotensin-converting enzyme inhibitors. *Nephrology (Carlton)* 2007; **12**: 529–531.
151. Colquitt JL, Kirby J, Green C *et al.* The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. *Health Technol Assess* 2007; **11**: iii–iv, ix–xi, 1–93.
152. D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. *Semin Nephrol* 2003; **23**: 117–134.
153. Braden GL, Mulhern JG, O'Shea MH *et al.* Changing incidence of glomerular diseases in adults. *Am J Kidney Dis* 2000; **35**: 878–883.
154. Haas M, Meehan SM, Karrison TG *et al.* Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976 to 1979 and 1995 to 1997. *Am J Kidney Dis* 1997; **30**: 621–631.
155. Deegens JK, Steenbergen EJ, Wetzels JF. Review on diagnosis and treatment of focal segmental glomerulosclerosis. *Neth J Med* 2008; **66**: 3–12.
156. Deegens JK, Dijkman HB, Borm GF *et al.* Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. *Kidney Int* 2008; **74**: 1568–1576.
157. Aucella F, De Bonis P, Gatta G *et al.* Molecular analysis of NPHS2 and ACTN4 genes in a series of 33 Italian patients affected by adult-onset nonfamilial focal segmental glomerulosclerosis. *Nephron Clin Pract* 2005; **99**: c31–c36.
158. Caridi G, Bertelli R, Scolari F *et al.* Podocin mutations in sporadic focal-segmental glomerulosclerosis occurring in adulthood. *Kidney Int* 2003; **64**: 365.
159. Gigante M, Pontrelli P, Montemurno E *et al.* CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). *Nephrol Dial Transplant* 2009; **24**: 1858–1864.
160. He N, Zahirieh A, Mei Y *et al.* Recessive NPHS2 (Podocin) mutations are rare in adult-onset idiopathic focal segmental glomerulosclerosis. *Clin J Am Soc Nephrol* 2007; **2**: 31–37.
161. Machuca E, Hummel A, Nevo F *et al.* Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant. *Kidney Int* 2009; **75**: 727–735.
162. Santin S, Ars E, Rossetti S *et al.* TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 2009; **24**: 3089–3096.
163. Santin S, Garcia-Maset R, Ruiz P *et al.* Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. *Kidney Int* 2009; **76**: 1268–1276.
164. Genovese G, Friedman DJ, Ross MD *et al.* Association of trypanolytic ApoL1 variants with kidney disease in African Americans. *Science* 2010; **329**: 841–845.
165. Cameron JS, Turner DR, Ogg CS *et al.* The long-term prognosis of patients with focal segmental glomerulosclerosis. *Clin Nephrol* 1978; **10**: 213–218.
166. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. *Am J Kidney Dis* 1994; **23**: 773–783.
167. Velosa JA, Donadio Jr JV, Holley KE. Focal sclerosing glomerulonephropathy: a clinicopathologic study. *Mayo Clin Proc* 1975; **50**: 121–133.
168. Banfi G, Moriggi M, Sabadini E *et al.* The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. *Clin Nephrol* 1991; **36**: 53–59.
169. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. *Am J Kidney Dis* 1998; **32**: 72–79.
170. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. *Kidney Int* 2002; **62**: 2301–2310.
171. Rydel JJ, Korbet SM, Borok RZ *et al.* Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. *Am J Kidney Dis* 1995; **25**: 534–542.
172. Goumenos DS, Tsagalis G, El Nahas AM *et al.* Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. *Nephron Clin Pract* 2006; **104**: c75–c82.
173. Pei Y, Cattran D, Delmore T *et al.* Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. *Am J Med* 1987; **82**: 938–944.
174. Stirling CM, Mathieson P, Boulton-Jones JM *et al.* Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. *QJM* 2005; **98**: 443–449.
175. Wehrmann M, Bohle A, Held H *et al.* Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. *Clin Nephrol* 1990; **33**: 115–122.
176. Caridi G, Gigante M, Ravani P *et al.* Clinical features and long-term outcome of nephrotic syndrome associated with heterozygous NPHS1 and NPHS2 mutations. *Clin J Am Soc Nephrol* 2009; **4**: 1065–1072.
177. Beaufils H, Alphonse JC, Guedon J *et al.* Focal glomerulosclerosis: natural history and treatment. A report of 70 cases. *Nephron* 1978; **21**: 75–85.
178. Praga M, Martinez MA, Andres A *et al.* Acute renal failure and tubular dysfunction associated with minimal change nephrotic syndrome. *Nephrol Dial Transplant* 1989; **4**: 914–916.
179. Deegens JK, Assmann KJ, Steenbergen EJ *et al.* Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? *Neth J Med* 2005; **63**: 393–398.
180. Gupta K, Iskandar SS, Daeiagh P *et al.* Distribution of pathologic findings in individuals with nephrotic proteinuria according to serum albumin. *Nephrol Dial Transplant* 2008; **23**: 1595–1599.
181. Duncan N, Dhaygude A, Owen J *et al.* Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. *Nephrol Dial Transplant* 2004; **19**: 3062–3067.
182. Cattran DC, Alexopoulos E, Heering P *et al.* Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations. *Kidney Int* 2007; **72**: 1429–1447.
183. Shiiki H, Nishino T, Uyama H *et al.* Clinical and morphological predictors of renal outcome in adult patients with focal and segmental glomerulosclerosis (FSGS). *Clin Nephrol* 1996; **46**: 362–368.
184. Braun N, Schmutzler F, Lange C *et al.* Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. *Cochrane Database of Systematic Reviews* 2008: CD003233.
185. Cattran DC, Appel GB, Hebert LA *et al.* A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. *Kidney Int* 1999; **56**: 2220–2226.
186. Ghiggeri GM, Catarsi P, Scolari F *et al.* Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. *Clin Ther* 2004; **26**: 1411–1418.
187. Heering P, Braun N, Mullejans R *et al.* Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. *Am J Kidney Dis* 2004; **43**: 10–18.
188. Ittel TH, Clasen W, Fuhs M *et al.* Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. *Clin Nephrol* 1995; **44**: 156–162.
189. Melocoton TL, Kamil ES, Cohen AH *et al.* Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. *Am J Kidney Dis* 1991; **18**: 583–588.
190. Segarra A, Vila J, Pou L *et al.* Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. *Nephrol Dial Transplant* 2002; **17**: 655–662.
191. Abe S, Amagasaki Y, Konishi K *et al.* Idiopathic membranous glomerulonephritis: aspects of geographical differences. *J Clin Pathol* 1986; **39**: 1193–1198.
192. Cahen R, Francois B, Trollet P *et al.* Aetiology of membranous glomerulonephritis: a prospective study of 82 adult patients. *Nephrol Dial Transplant* 1989; **4**: 172–180.
193. Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson JL, Schwartz MM (eds). *Heptinstall's Pathology of the Kidney*, 6th edn, vol. 1. Lippincott Williams & Wilkins: Philadelphia, PA, 2007, pp 205–251.
194. Kuroki A, Shibata T, Honda H *et al.* Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. *Intern Med* 2002; **41**: 936–942.
195. Ohtani H, Wakui H, Komatsuda A *et al.* Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. *Nephrol Dial Transplant* 2004; **19**: 574–579.
196. Zeng CH, Chen HM, Wang RS *et al.* Etiology and clinical characteristics of membranous nephropathy in Chinese patients. *Am J Kidney Dis* 2008; **52**: 691–698.

197. Honkanen E. Survival in idiopathic membranous glomerulonephritis. *Clin Nephrol* 1986; **25**: 122–128.
198. Ehrenreich T, Porush JG, Churg J *et al*. Treatment of idiopathic membranous nephropathy. *N Engl J Med* 1976; **295**: 741–746.
199. Lefaucheur C, Stengel B, Nochy D *et al*. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. *Kidney Int* 2006; **70**: 1510–1517.
200. Beck Jr LH, Bonegio RG, Lambeau G *et al*. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. *N Engl J Med* 2009; **361**: 11–21.
201. Glasscock RJ. Secondary membranous glomerulonephritis. *Nephrol Dial Transplant* 1992; **7**(Suppl 1): 64–71.
202. Gluck MC, Gallo G, Lowenstein J *et al*. Membranous glomerulonephritis. Evolution of clinical and pathologic features. *Ann Intern Med* 1973; **78**: 1–12.
203. Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. *Am J Kidney Dis* 1993; **22**: 5–10.
204. Jha V, Ganguli A, Saha TK *et al*. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. *J Am Soc Nephrol* 2007; **18**: 1899–1904.
205. Passerini P, Ponticelli C. Membranous nephropathy. In: Ponticelli C, Glasscock R (eds). *Treatment of Primary Glomerulonephritis*, 2nd edn. Oxford University Press: Oxford, UK, 2009, pp 261–312.
206. Glasscock RJ. Diagnosis and natural course of membranous nephropathy. *Semin Nephrol* 2003; **23**: 324–332.
207. Cameron JS. Membranous nephropathy and its treatment. *Nephrol Dial Transplant* 1992; **7**(Suppl 1): 72–79.
208. Cattran DC. Idiopathic membranous glomerulonephritis. *Kidney Int* 2001; **59**: 1983–1994.
209. Donadio Jr JV, Torres VE, Velosa JA *et al*. Idiopathic membranous nephropathy: the natural history of untreated patients. *Kidney Int* 1988; **33**: 708–715.
210. Erwin DT, Donadio Jr JV, Holley KE. The clinical course of idiopathic membranous nephropathy. *Mayo Clin Proc* 1973; **48**: 697–712.
211. Hopper Jr J, Trew PA, Biava CG. Membranous nephropathy: its relative benignity in women. *Nephron* 1981; **29**: 18–24.
212. Murphy BF, Fairley KF, Kincaid-Smith PS. Idiopathic membranous glomerulonephritis: long-term follow-up in 139 cases. *Clin Nephrol* 1988; **30**: 175–181.
213. Row PG, Cameron JS, Turner DR *et al*. Membranous nephropathy. Long-term follow-up and association with neoplasia. *Q J Med* 1975; **44**: 207–239.
214. Schieppati A, Mosconi L, Perna A *et al*. Prognosis of untreated patients with idiopathic membranous nephropathy. *N Engl J Med* 1993; **329**: 85–89.
215. Polanco N, Gutierrez E, Covarsi A *et al*. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. *J Am Soc Nephrol* 2010; **21**: 697–704.
216. Cattran D. Management of membranous nephropathy: when and what for treatment. *J Am Soc Nephrol* 2005; **16**: 1188–1194.
217. Cattran DC, Reich HN, Beanlands HJ *et al*. The impact of sex in primary glomerulonephritis. *Nephrol Dial Transplant* 2008; **23**: 2247–2253.
218. Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. *Kidney Int* 1992; **42**: 960–966.
219. Cattran DC, Pei Y, Greenwood CM *et al*. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. *Kidney Int* 1997; **51**: 901–907.
220. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. *Clin J Am Soc Nephrol* 2008; **3**: 905–919.
221. Laluck Jr BJ, Cattran DC. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. *Am J Kidney Dis* 1999; **33**: 1026–1032.
222. Troyanov S, Wall CA, Miller JA *et al*. Idiopathic membranous nephropathy: definition and relevance of a partial remission. *Kidney Int* 2004; **66**: 1199–1205.
223. Kosmadakis G, Filiopoulos V, Georgoulis C *et al*. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. *Scand J Urol Nephrol* 2010; **44**: 251–256.
224. Reichert LJ, Koene RA, Wetzels JF. Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. *J Am Soc Nephrol* 1995; **6**: 1666–1669.
225. Reichert LJ, Koene RA, Wetzels JF. Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. *Clin Nephrol* 1997; **48**: 79–84.
226. Donadio Jr JV, Holley KE, Anderson CF *et al*. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. *Kidney Int* 1974; **6**: 431–439.
227. Murphy BF, McDonald I, Fairley KF *et al*. Randomized controlled trial of cyclophosphamide, warfarin and dipyrindamole in idiopathic membranous glomerulonephritis. *Clin Nephrol* 1992; **37**: 229–234.
228. Shearman JD, Yin ZG, Aarons I *et al*. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy. *Clin Nephrol* 1988; **30**: 320–329.
229. Ponticelli C, Zucchelli P, Imbasciati E *et al*. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. *N Engl J Med* 1984; **310**: 946–950.
230. Falk RJ, Hogan SL, Muller KE *et al*. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. *Ann Intern Med* 1992; **116**: 438–445.
231. McQuarrie EP, Stirling CM, Geddes CC. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy. *Nephrol Dial Transplant* 2012; **27**: 235–242.
232. Ponticelli C, Zucchelli P, Passerini P *et al*. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. *N Engl J Med* 1989; **320**: 8–13.
233. Ponticelli C, Zucchelli P, Passerini P *et al*. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. *Kidney Int* 1995; **48**: 1600–1604.
234. Ponticelli C, Zucchelli P, Passerini P *et al*. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. *N Engl J Med* 1992; **327**: 599–603.
235. Ponticelli C, Altieri P, Scolari F *et al*. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. *J Am Soc Nephrol* 1998; **9**: 444–450.
236. Hogan SL, Muller KE, Jennette JC *et al*. A review of therapeutic studies of idiopathic membranous glomerulopathy. *Am J Kidney Dis* 1995; **25**: 862–875.
237. Imperiale TF, Goldfarb S, Berns JS. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. *J Am Soc Nephrol* 1995; **5**: 1553–1558.
238. Jindal K, West M, Bear R *et al*. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. *Am J Kidney Dis* 1992; **19**: 61–67.
239. Perna A, Schieppati A, Zamora J *et al*. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. *Am J Kidney Dis* 2004; **44**: 385–401.
240. West ML, Jindal KK, Bear RA *et al*. A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis. *Kidney Int* 1987; **32**: 579–584.
241. Hofstra JM, Branten AJ, Wirtz JJ *et al*. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. *Nephrol Dial Transplant* 2010; **25**: 129–136.
242. Branten AJ, Reichert LJ, Koene RA *et al*. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. *QJM* 1998; **91**: 359–366.
243. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. *Nephrol Dial Transplant* 2004; **19**: 1142–1148.
244. Rose GA, Black DAK, Members of Working Party. Controlled trial of azathioprine and prednisone in chronic renal disease. Report by Medical Research Council Working Party. *Br Med J* 1971; **2**: 239–241.
245. Western Canadian Glomerulonephritis Study Group. Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. *Can Med Assoc J* 1976; **115**: 1209–1210.
246. Lagrue G, Bernard D, Bariety J *et al*. [Treatment with chlorambucil and azathioprine in primary glomerulonephritis. Results of a 'controlled' study]. *J Urol Nephrol (Paris)* 1975; **81**: 655–672.
247. Ambalavanan S, Fauvel JP, Sibley RK *et al*. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. *J Am Soc Nephrol* 1996; **7**: 290–298.

248. Guasch A, Suranyi M, Newton L *et al*. Short-term responsiveness of membranous glomerulopathy to cyclosporine. *Am J Kidney Dis* 1992; **20**: 472–481.
249. Cattran DC, Appel GB, Hebert LA *et al*. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. *Kidney Int* 2001; **59**: 1484–1490.
250. Alexopoulos E, Papagianni A, Tsamelashvili M *et al*. Induction and long-term treatment with cyclosporin A in membranous glomerulonephritis with the nephrotic syndrome (abstract). *J Am Soc Nephrol* 2005; **16**: 780A.
251. Cattran DC, Greenwood C, Ritchie S *et al*. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. *Kidney Int* 1995; **47**: 1130–1135.
252. DeSanto NG, Capodicasa G, Giordano C. Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. *Am J Nephrol* 1987; **7**: 74–76.
253. Rostoker G, Belghiti D, Ben Maadi A *et al*. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. *Nephron* 1993; **63**: 335–341.
254. Praga M, Barrio V, Juarez GF *et al*. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. *Kidney Int* 2007; **71**: 924–930.
255. Bruns FJ, Adler S, Fraley DS *et al*. Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. *Ann Intern Med* 1991; **114**: 725–730.
256. Mathieson PW, Turner AN, Maidment CG *et al*. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. *Lancet* 1988; **2**: 869–872.
257. Torres A, Dominguez-Gil B, Carreno A *et al*. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. *Kidney Int* 2002; **61**: 219–227.
258. Warwick GL, Geddes CG, Boulton-Jones JM. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. *Q J Med* 1994; **87**: 223–229.
259. Chen M, Li H, Li XY *et al*. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. *Am J Med Sci* 2010; **339**: 233–238.
260. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. *N Engl J Med* 1979; **301**: 1301–1306.
261. Cattran DC, Delmore T, Roscoe J *et al*. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. *N Engl J Med* 1989; **320**: 210–215.
262. Shiiki H, Saito T, Nishitani Y *et al*. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. *Kidney Int* 2004; **65**: 1400–1407.
263. Branten AJ, du Buf-Vereijken PW, Vervloet M *et al*. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. *Am J Kidney Dis* 2007; **50**: 248–256.
264. Chan TM, Lin AW, Tang SC *et al*. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. *Nephrology (Carlton)* 2007; **12**: 576–581.
- 264a. Senthil Nayagam L, Ganguli A, Rathi M *et al*. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. *Nephrol Dial Transplant* 2008; **23**: 1926–1930.
265. Dussol B, Morange S, Burtey S *et al*. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. *Am J Kidney Dis* 2008; **52**: 699–705.
266. Remuzzi G, Chiurciu C, Abbate M *et al*. Rituximab for idiopathic membranous nephropathy. *Lancet* 2002; **360**: 923–924.
267. Ruggenti P, Chiurciu C, Brusegan V *et al*. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. *J Am Soc Nephrol* 2003; **14**: 1851–1857.
268. Ruggenti P, Chiurciu C, Abbate M *et al*. Rituximab for idiopathic membranous nephropathy: who can benefit? *Clin J Am Soc Nephrol* 2006; **1**: 738–748.
269. Fervenza FC, Cosio FG, Erickson SB *et al*. Rituximab treatment of idiopathic membranous nephropathy. *Kidney Int* 2008; **73**: 117–125.
270. Cravedi P, Ruggenti P, Sghirlanzoni MC *et al*. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. *Clin J Am Soc Nephrol* 2007; **2**: 932–937.
271. Fervenza FC, Abraham RS, Erickson SB *et al*. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. *Clin J Am Soc Nephrol* 2010; **5**: 2188–2198.
272. Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. *Nephrol Dial Transplant* 2004; **19**: 1305–1307.
273. Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. *Kidney Int* 1999; **56**: 1534–1543.
274. Ponticelli C, Passerini P, Salvadori M *et al*. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotrophic hormone in idiopathic membranous nephropathy. *Am J Kidney Dis* 2006; **47**: 233–240.
275. Ahmed S, Rahman M, Alam MR *et al*. Methyl prednisolone plus chlorambucil as compared with prednisolone alone for the treatment of idiopathic membranous nephropathy. A preliminary study. *Bangladesh Renal J* 1994; **13**: 51–54.
276. Reichert LJ, Huysmans FT, Assmann K *et al*. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. *Ann Intern Med* 1994; **121**: 328–333.
277. Bomback AS, Derebail VK, McGregor JG *et al*. Rituximab therapy for membranous nephropathy: a systematic review. *Clin J Am Soc Nephrol* 2009; **4**: 734–744.
278. Nasr SH, Said SM, Valeri AM *et al*. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. *Clin J Am Soc Nephrol* 2009; **4**: 299–308.
279. Troxell ML, Saxena AB, Kambham N. Concurrent anti-glomerular basement membrane disease and membranous glomerulonephritis: a case report and literature review. *Clin Nephrol* 2006; **66**: 120–127.
280. Waldman M, Austin III HA. Controversies in the treatment of idiopathic membranous nephropathy. *Nat Rev Nephrol* 2009; **5**: 469–479.
281. Ponticelli C, Passerini P, Altieri P *et al*. Remissions and relapses in idiopathic membranous nephropathy. *Nephrol Dial Transplant* 1992; **7**(Suppl 1): 85–90.
282. Suki WN, Trimarchi H, Frommer JP. Relapsing membranous nephropathy. Response to therapy of relapses compared to that of the original disease. *Am J Nephrol* 1999; **19**: 474–479.
283. du Buf-Vereijken PW, Wetzels JF. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. *Nephrol Dial Transplant* 2004; **19**: 2036–2043.
284. Faurischou M, Sorensen IJ, Mellemkjaer L *et al*. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. *J Rheumatol* 2008; **35**: 100–105.
285. Segarra A, Praga M, Ramos N *et al*. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. *Clin J Am Soc Nephrol* 2009; **4**: 1083–1088.
286. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. *Kidney Int* 1978; **13**: 159–165.
287. USRDS 2008. *Annual data report: Atlas of chronic kidney disease*. Atlas of end-stage renal disease. US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2008.
288. Menon S, Valentini RP. Membranous nephropathy in children: clinical presentation and therapeutic approach. *Pediatr Nephrol* 2010; **25**: 1419–1428.
289. Makker SP. Treatment of membranous nephropathy in children. *Semin Nephrol* 2003; **23**: 379–385.
290. Watson AR, Rance CP, Bain J. Long term effects of cyclophosphamide on testicular function. *Br Med J (Clin Res Ed)* 1985; **291**: 1457–1460.
291. Habib R, Kleinknecht C, Gubler MC. Extramembranous glomerulonephritis in children: report of 50 cases. *J Pediatr* 1973; **82**: 754–766.
292. Olbing H, Greifer I, Bennett BP *et al*. Idiopathic membranous nephropathy in children. *Kidney Int* 1973; **3**: 381–390.
293. Chan WC, Tsao YC. Diffuse membranous glomerulonephritis in children. *J Clin Pathol* 1966; **19**: 464–469.
294. Trainin EB, Boichis H, Spitzer A *et al*. Idiopathic membranous nephropathy. Clinical course in children. *N Y State J Med* 1976; **76**: 357–360.
295. Latham P, Poucell S, Koresaar A *et al*. Idiopathic membranous glomerulopathy in Canadian children: a clinicopathologic study. *J Pediatr* 1982; **101**: 682–685.

296. Ramirez F, Brouhard BH, Travis LB *et al.* Idiopathic membranous nephropathy in children. *J Pediatr* 1982; **101**: 677–681.
297. Tsukahara H, Takahashi Y, Yoshimoto M *et al.* Clinical course and outcome of idiopathic membranous nephropathy in Japanese children. *Pediatr Nephrol* 1993; **7**: 387–391.
298. Lee BH, Cho HY, Kang HG *et al.* Idiopathic membranous nephropathy in children. *Pediatr Nephrol* 2006; **21**: 1707–1715.
299. Chen A, Frank R, Vento S *et al.* Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. *BMC Nephrol* 2007; **8**: 11.
300. Valentini RP, Mattoo TK, Kapur G *et al.* Membranous glomerulonephritis: treatment response and outcome in children. *Pediatr Nephrol* 2009; **24**: 301–308.
301. Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? *Nephron* 1993; **63**: 249–254.
302. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. *J Am Soc Nephrol* 2007; **18**: 2221–2225.
303. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. *Kidney Int* 1994; **45**: 578–585.
304. Glassock RJ. Membranoproliferative glomerulonephritis. In: Molony DA, Craig JC (eds). *Evidence-based Nephrology*, 1st edn. John Wiley & Sons: Hoboken, NJ, 2008, pp 183–195.
305. Glassock RJ. Membranoproliferative glomerulonephritis. In: Ponticelli C, Glassock R (eds). *Treatment of Primary Glomerulonephritis*, 2nd edn. Oxford University Press: Oxford, UK, 2009, pp 375–398.
306. West CD, McAdams AJ, McConville JM *et al.* Hypocomplementemic and normocomplementemic persistent (chronic) glomerulonephritis; clinical and pathologic characteristics. *J Pediatr* 1965; **67**: 1089–1112.
307. Fakhouri F, Fremeaux-Bacchi V, Noel LH *et al.* C3 glomerulopathy: a new classification. *Nat Rev Nephrol* 2010; **6**: 494–499.
308. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. *Semin Nephrol* 2011; **31**: 341–348.
309. Appel GB, Cook HT, Hageman G *et al.* Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. *J Am Soc Nephrol* 2005; **16**: 1392–1403.
310. Holley KE, Donadio JV. Membranoproliferative glomerulonephritis. In: Tisher CC, Brenner BM (eds). *Renal Pathology (with Clinical and Functional Correlations)*, 2nd edn. JB Lippincott and Co: Philadelphia, PA, 1994, pp 294–329.
311. Servais A, Fremeaux-Bacchi V, Salomon R *et al.* Mutations in complement regulatory genes, Factor H, I and CD46 and C3 nephritic factor predispose to membranoproliferative glomerulonephritis with isolated mesangial C3 deposition (abstract). *J Am Soc Nephrol* 2005; **16**: 51A.
312. Schwartz R, Rother U, Anders D *et al.* Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. *Pediatr Allergy Immunol* 2001; **12**: 166–172.
313. Smith RJ, Alexander J, Barlow PN *et al.* New approaches to the treatment of dense deposit disease. *J Am Soc Nephrol* 2007; **18**: 2447–2456.
314. Asinobi AO, Gbadegesin RA, Adeyemo AA *et al.* The predominance of membranoproliferative glomerulonephritis in childhood nephrotic syndrome in Ibadan, Nigeria. *West Afr J Med* 1999; **18**: 203–206.
315. Donadio Jr JV, Anderson CF, Mitchell III JC *et al.* Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. *N Engl J Med* 1984; **310**: 1421–1426.
316. Donadio Jr JV, Offord KP. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. *Am J Kidney Dis* 1989; **14**: 445–451.
317. Emre S, Sirin A, Alpay H *et al.* Pulse methylprednisolone therapy in children with membranoproliferative glomerulonephritis. *Acta Paediatr Jpn* 1995; **37**: 626–629.
318. Zauner I, Bohler J, Braun N *et al.* Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). *Nephrol Dial Transplant* 1994; **9**: 619–622.
319. McEnery PT. Membranoproliferative glomerulonephritis: the Cincinnati experience—cumulative renal survival from 1957 to 1989. *J Pediatr* 1990; **116**: S109–S114.
320. McEnery PT, McAdams AJ, West CD. The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis. *Medicine (Baltimore)* 1985; **64**: 401–424.
321. Tarshish P, Bernstein J, Tobin JN *et al.* Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone—a report of the International Study of Kidney Disease in Children. *Pediatr Nephrol* 1992; **6**: 123–130.
322. Warady BA, Guggenheim SJ, Sedman A *et al.* Prednisone therapy of membranoproliferative glomerulonephritis in children. *J Pediatr* 1985; **107**: 702–707.
323. Bergstein JM, Andreoli SP. Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. *Pediatr Nephrol* 1995; **9**: 268–271.
324. Cattran DC, Cardella CJ, Roscoe JM *et al.* Results of a controlled drug trial in membranoproliferative glomerulonephritis. *Kidney Int* 1985; **27**: 436–441.
325. Chapman SJ, Cameron JS, Chantler C *et al.* Treatment of mesangiocapillary glomerulonephritis in children with combined immunosuppression and anticoagulation. *Arch Dis Child* 1980; **55**: 446–451.
326. Faedda R, Satta A, Tanda F *et al.* Immunosuppressive treatment of membranoproliferative glomerulonephritis. *Nephron* 1994; **67**: 59–65.
327. Jones G, Juszcak M, Kingdon E *et al.* Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. *Nephrol Dial Transplant* 2004; **19**: 3160–3164.
328. Levin A. Management of membranoproliferative glomerulonephritis: evidence-based recommendations. *Kidney Int Suppl* 1999; **70**: S41–S46.
329. Tiller D, Clarkson AR, Mathew T. A prospective randomized trial of the use of cyclophosphamide, dipyridamole and warfarin in membranous and membranoproliferative glomerulonephritis. In: Robinson R, Glassock R, Tisher CC, Andreoli T, *et al.* (eds). *Proceedings of the 8th International Congress of Nephrology*. Karger: Basel, Switzerland, 1981, pp 345–351.
330. Montseny JJ, Meyrier A, Kleinknecht D *et al.* The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature. *Medicine (Baltimore)* 1995; **74**: 63–73.
331. Moroni G, Pozzi C, Quaglini S *et al.* Long-term prognosis of diffuse proliferative glomerulonephritis associated with infection in adults. *Nephrol Dial Transplant* 2002; **17**: 1204–1211.
332. Nasr SH, Markowitz GS, Stokes MB *et al.* Acute postinfectious glomerulonephritis in the modern era: experience with 86 adults and review of the literature. *Medicine (Baltimore)* 2008; **87**: 21–32.
333. Moroni G, Ponticelli C. Acute post-infectious glomerulonephritis. In: Ponticelli C, Glassock R (eds). *Treatment of Primary Glomerulonephritis*, 2nd edn. Oxford University Press: Oxford, UK, 2009, pp 153–177.
334. Rodriguez-Isturbe B, Musser JM. The current state of poststreptococcal glomerulonephritis. *J Am Soc Nephrol* 2008; **19**: 1855–1864.
335. Batsford SR, Mezzano S, Mihatsch M *et al.* Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin B (SPE B) or GAPDH? *Kidney Int* 2005; **68**: 1120–1129.
336. Yoshizawa N, Yamakami K, Fujino M *et al.* Nephritis-associated plasmin receptor and acute poststreptococcal glomerulonephritis: characterization of the antigen and associated immune response. *J Am Soc Nephrol* 2004; **15**: 1785–1793.
337. Baldwin DS. Poststreptococcal glomerulonephritis. A progressive disease? *Am J Med* 1977; **62**: 1–11.
338. Habib G, Hoen B, Tornos P *et al.* Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. *Eur Heart J* 2009; **30**: 2369–2413.
339. Hoen B, Alla F, Selton-Suty C *et al.* Changing profile of infective endocarditis: results of a 1-year survey in France. *JAMA* 2002; **288**: 75–81.
340. Koya D, Shibuya K, Kikkawa R *et al.* Successful recovery of infective endocarditis-induced rapidly progressive glomerulonephritis by steroid therapy combined with antibiotics: a case report. *BMC Nephrol* 2004; **5**: 18.
341. Iwata Y, Ohta S, Kawai K *et al.* Shunt nephritis with positive titers for ANCA specific for proteinase 3. *Am J Kidney Dis* 2004; **43**: e11–e16.
342. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. *Kidney Int Suppl* 2008: S1–S99.
343. Alter MJ. Epidemiology of hepatitis C virus infection. *World J Gastroenterol* 2007; **13**: 2436–2441.
344. Poynard T, Yuen MF, Ratziu V *et al.* Viral hepatitis C. *Lancet* 2003; **362**: 2095–2100.

345. Williams R. Global challenges in liver disease. *Hepatology* 2006; **44**: 521–526.
346. Perico N, Cattaneo D, Bikbov B *et al*. Hepatitis C infection and chronic renal diseases. *Clin J Am Soc Nephrol* 2009; **4**: 207–220.
347. Johnson RJ, Gretch DR, Yamabe H *et al*. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. *N Engl J Med* 1993; **328**: 465–470.
348. Meyers CM, Seeff LB, Stehman-Breen CO *et al*. Hepatitis C and renal disease: an update. *Am J Kidney Dis* 2003; **42**: 631–657.
349. Roccatello D, Fornasieri A, Giachino O *et al*. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. *Am J Kidney Dis* 2007; **49**: 69–82.
350. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. *Kidney Int* 1998; **54**: 650–671.
351. Arase Y, Ikeda K, Murahima N *et al*. Glomerulonephritis in autopsy cases with hepatitis C virus infection. *Intern Med* 1998; **37**: 836–840.
352. Kamar N, Izopet J, Alric L *et al*. Hepatitis C virus-related kidney disease: an overview. *Clin Nephrol* 2008; **69**: 149–160.
353. Markowitz GS, Cheng JT, Colvin RB *et al*. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. *J Am Soc Nephrol* 1998; **9**: 2244–2252.
354. Sabry A, A EA, Sheashaa H *et al*. HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis. *Virology* 2005; **334**: 10–16.
355. Ghany MG, Strader DB, Thomas DL *et al*. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 2009; **49**: 1335–1374.
356. Fried MW, Shiffman ML, Reddy KR *et al*. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975–982.
357. Hadziyannis SJ, Sette Jr H, Morgan TR *et al*. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; **140**: 346–355.
358. Manns MP, McHutchison JG, Gordon SC *et al*. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958–965.
359. Johnson RJ, Gretch DR, Couser WG *et al*. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. *Kidney Int* 1994; **46**: 1700–1704.
360. Misiani R, Bellavita P, Fenili D *et al*. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. *N Engl J Med* 1994; **330**: 751–756.
361. Cresta P, Musset L, Cacoub P *et al*. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. *Gut* 1999; **45**: 122–128.
362. Komatsuda A, Imai H, Wakui H *et al*. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. *Intern Med* 1996; **35**: 529–533.
363. Mazza C, Panarello G, Carniello S *et al*. Interferon versus steroids in patients with hepatitis C virus-associated cryoglobulinaemic glomerulonephritis. *Dig Liver Dis* 2000; **32**: 708–715.
364. Cid MC, Hernandez-Rodriguez J, Robert J *et al*. Interferon-alpha may exacerbate cryoglobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. *Arthritis Rheum* 1999; **42**: 1051–1055.
365. Suzuki T, Yonemura K, Miyaji T *et al*. Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis. *Intern Med* 2001; **40**: 708–712.
366. Garini G, Allegri L, Lannuzzella F *et al*. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. *Acta Biomed* 2007; **78**: 51–59.
367. Bruchfeld A, Lindahl K, Stahle L *et al*. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. *Nephrol Dial Transplant* 2003; **18**: 1573–1580.
368. Garini G, Allegri L, Carnevali L *et al*. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. *Am J Kidney Dis* 2001; **38**: E35.
369. Rossi P, Bertani T, Baio P *et al*. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. *Kidney Int* 2003; **63**: 2236–2241.
370. Sabry AA, Sobh MA, Sheashaa HA *et al*. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. *Nephrol Dial Transplant* 2002; **17**: 1924–1930.
371. Alric L, Plaisier E, Thebault S *et al*. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. *Am J Kidney Dis* 2004; **43**: 617–623.
372. Cacoub P, Saadoun D, Limal N *et al*. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. *Arthritis Rheum* 2005; **52**: 911–915.
373. Mazza C, Zorat F, Caizzi M *et al*. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. *J Hepatol* 2005; **42**: 632–638.
374. Saadoun D, Resche-Rigon M, Thibault V *et al*. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. *Arthritis Rheum* 2006; **54**: 3696–3706.
375. Fabrizi F, Bruchfeld A, Mangano S *et al*. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. *Int J Artif Organs* 2007; **30**: 212–219.
376. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. *Kidney Int* 2009; **76**: 818–824.
377. Koziolok MJ, Scheel A, Bramlage C *et al*. Effective treatment of hepatitis C-associated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy. *Clin Nephrol* 2007; **67**: 245–249.
378. Ahmed MS, Wong CF. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? *J Nephrol* 2007; **20**: 350–356.
379. Cacoub P, Delluc A, Saadoun D *et al*. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? *Ann Rheum Dis* 2008; **67**: 283–287.
380. Sansonno D, De Re V, Lauletta G *et al*. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. *Blood* 2003; **101**: 3818–3826.
381. Saadoun D, Resche-Rigon M, Sene D *et al*. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. *Ann Rheum Dis* 2008; **67**: 1431–1436.
382. Garini G, Allegri L, Carnevali ML *et al*. Successful treatment of severe/active cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection by means of the sequential administration of immunosuppressive and antiviral agents. *Nephrol Dial Transplant* 2006; **21**: 3333–3334.
383. Iannuzzella F, Vaglio A, Garini G. Management of hepatitis C virus-related mixed cryoglobulinemia. *Am J Med* 2010; **123**: 400–408.
384. Saadoun D, Resche Rigon M, Sene D *et al*. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. *Blood* 2010; **116**: 326–334; quiz 504–525.
385. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. *J Hepatol* 2009; **50**: 227–242.
386. Sorrell MF, Belongia EA, Costa J *et al*. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. *Ann Intern Med* 2009; **150**: 104–110.
387. Olsen SK, Brown Jr RS. Hepatitis B treatment: Lessons for the nephrologist. *Kidney Int* 2006; **70**: 1897–1904.
388. Appel G. Viral infections and the kidney: HIV, hepatitis B, and hepatitis C. *Cleve Clin J Med* 2007; **74**: 353–360.
389. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009; **50**: 661–662.
390. Sepkowitz KA. One disease, two epidemics—AIDS at 25. *N Engl J Med* 2006; **354**: 2411–2414.
391. Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. *Ann Intern Med* 2003; **139**: 214–226.
392. Wyatt CM, Klotman PE. HIV-1 and HIV-associated nephropathy 25 years later. *Clin J Am Soc Nephrol* 2007; **2**(Suppl 1): S20–S24.
393. Genovesi G, Tonna SJ, Knob AU *et al*. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. *Kidney Int* 2010; **78**: 698–704.
394. Cohen SD, Kimmel PL. Immune complex renal disease and human immunodeficiency virus infection. *Semin Nephrol* 2008; **28**: 535–544.
395. Szczec LA, Gupta SK, Habash R *et al*. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. *Kidney Int* 2004; **66**: 1145–1152.
396. Szczec LA, Hoover DR, Feldman JG *et al*. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. *Clin Infect Dis* 2004; **39**: 1199–1206.

397. El-Sadr WM, Lundgren JD, Neaton JD *et al.* CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med* 2006; **355**: 2283–2296.
398. Kalayjian RC, Franceschini N, Gupta SK *et al.* Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. *AIDS* 2008; **22**: 481–487.
399. Krawczyk CS, Holmberg SD, Moorman AC *et al.* Factors associated with chronic renal failure in HIV-infected ambulatory patients. *AIDS* 2004; **18**: 2171–2178.
400. Peters PJ, Moore DM, Mermin J *et al.* Antiretroviral therapy improves renal function among HIV-infected Ugandans. *Kidney Int* 2008; **74**: 925–929.
401. Reid A, Stohr W, Walker AS *et al.* Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. *Clin Infect Dis* 2008; **46**: 1271–1281.
402. Gupta SK, Parker RA, Robbins GK *et al.* The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: results from a randomized trial. *Nephrol Dial Transplant* 2005; **20**: 2237–2242.
403. Gupta SK, Smurzynski M, Franceschini N *et al.* The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. *Antivir Ther* 2009; **14**: 543–549.
404. Longenecker CT, Scherzer R, Bacchetti P *et al.* HIV viremia and changes in kidney function. *AIDS* 2009; **23**: 1089–1096.
405. Wyatt CM, Morgello S, Katz-Malamed R *et al.* The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. *Kidney Int* 2009; **75**: 428–434.
406. Wyatt CM, Winston JA, Malvestutto CD *et al.* Chronic kidney disease in HIV infection: an urban epidemic. *AIDS* 2007; **21**: 2101–2103.
407. Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with “lupus-like” features: a clinicopathologic study of 14 cases. *Kidney Int* 2005; **67**: 1381–1390.
408. Fine DM, Perazella MA, Lucas GM *et al.* Kidney biopsy in HIV: beyond HIV-associated nephropathy. *Am J Kidney Dis* 2008; **51**: 504–514.
409. Gertholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. *Kidney Int* 2006; **69**: 1885–1891.
410. Han TM, Naicker S, Ramdial PK *et al.* A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. *Kidney Int* 2006; **69**: 2243–2250.
411. Cohen SD, Kimmel PL. Renal biopsy is necessary for the diagnosis of HIV-associated renal diseases. *Nat Clin Pract Nephrol* 2009; **5**: 22–23.
412. Babut-Gay ML, Echard M, Kleinknecht D *et al.* Zidovudine and nephropathy with human immunodeficiency virus (HIV) infection. *Ann Intern Med* 1989; **111**: 856–857.
413. Ifudu O, Rao TK, Tan CC *et al.* Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. *Am J Nephrol* 1995; **15**: 217–221.
414. Kirchner JT. Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature. *AIDS Read* 2002; **12**: 103–105, 110–102.
415. Szczech LA, Edwards LJ, Sanders LL *et al.* Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. *Clin Nephrol* 2002; **57**: 336–341.
416. Lucas GM, Eustace JA, Sozio S *et al.* Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. *AIDS* 2004; **18**: 541–546.
417. Atta MG, Gallant JE, Rahman MH *et al.* Antiretroviral therapy in the treatment of HIV-associated nephropathy. *Nephrol Dial Transplant* 2006; **21**: 2809–2813.
418. Kalayjian RC. The treatment of HIV-associated nephropathy. *Adv Chronic Kidney Dis* 2010; **17**: 59–71.
419. Eustace JA, Nuermberger E, Choi M *et al.* Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. *Kidney Int* 2000; **58**: 1253–1260.
420. Laradi A, Mallet A, Beaufils H *et al.* HIV-associated nephropathy: outcome and prognosis factors. Groupe d' Etudes Nephrologiques d'Ile de France. *J Am Soc Nephrol* 1998; **9**: 2327–2335.
421. Smith MC, Austen JL, Carey JT *et al.* Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. *Am J Med* 1996; **101**: 41–48.
422. Ingulli E, Tejani A, Fikrig S *et al.* Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. *J Pediatr* 1991; **119**: 710–716.
423. Yahaya I, Uthman AO, Uthman MM. Interventions for HIV-associated nephropathy. *Cochrane Database Syst Rev* 2009: CD007183.
424. Elewa U, Sandri AM, Rizza SA *et al.* Treatment of HIV-associated nephropathies. *Nephron Clin Pract* 2011; **118**: c346–c354.
425. Novak JE, Szczech LA (eds.) HIV and kidney disease. *Adv Chronic Kidney Dis* 2010; **17**: 1–111.
426. Chitsulo L, Engels D, Montresor A *et al.* The global status of schistosomiasis and its control. *Acta Trop* 2000; **77**: 41–51.
427. Chugh KS, Harries AD, Dahniya MH *et al.* Urinary schistosomiasis in Maiduguri, north east Nigeria. *Ann Trop Med Parasitol* 1986; **80**: 593–599.
428. Abdurrahman MB, Attah B, Narayana PT. Clinicopathological features of hepatosplenic schistosomiasis in children. *Ann Trop Paediatr* 1981; **1**: 5–11.
429. Abu-Romeh SH, van der Meulen J, Cozma MC *et al.* Renal diseases in Kuwait. Experience with 244 renal biopsies. *Int Urol Nephrol* 1989; **21**: 25–29.
430. Andrade ZA, Andrade SG, Sadigursky M. Renal changes in patients with hepatosplenic schistosomiasis. *Am J Trop Med Hyg* 1971; **20**: 77–83.
431. Chandra Shekhar K, Pathmanathan R. Schistosomiasis in Malaysia. *Rev Infect Dis* 1987; **9**: 1026–1037.
432. Falcao HA, Gould DB. Immune complex nephropathy in schistosomiasis. *Ann Intern Med* 1975; **83**: 148–154.
433. Musa AM, Asha HA, Veress B. Nephrotic syndrome in Sudanese patients with schistosomiasis mansoni infection. *Ann Trop Med Parasitol* 1980; **74**: 615–618.
434. Queiroz PF, Brito E, Martinelli R *et al.* Nephrotic syndrome in patients with *Schistosoma mansoni* infection. *Am J Trop Med Hyg* 1973; **22**: 622–628.
435. Rocha H, Cruz T, Brito E *et al.* Renal involvement in patients with hepatosplenic *Schistosomiasis mansoni*. *Am J Trop Med Hyg* 1976; **25**: 108–115.
436. Sobh MA, Moustafa FE, el-Housseini F *et al.* Schistosomal specific nephropathy leading to end-stage renal failure. *Kidney Int* 1987; **31**: 1006–1011.
437. Barsoum RS. Schistosomal glomerulopathies. *Kidney Int* 1993; **44**: 1–12.
438. Barsoum RS, Abdel-Rahman AY, Francis MR *et al.* Patterns of glomerular injury associated with hepato-splenic schistosomiasis. Proceedings of the XII Egyptian Congress of Nephrology. *Cairo, Egypt* 1992.
439. Sobh M, Moustafa F, el-Arbagy A *et al.* Nephropathy in asymptomatic patients with active *Schistosoma mansoni* infection. *Int Urol Nephrol* 1990; **22**: 37–43.
440. Rabello AL, Lambertucci JR, Freire MH *et al.* Evaluation of proteinuria in an area of Brazil endemic for schistosomiasis using a single urine sample. *Trans R Soc Trop Med Hyg* 1993; **87**: 187–189.
441. Eltout IA, Ghalib HW, Sualaiman S *et al.* Significance of eosinophilia in urinary schistosomiasis. A study using Hansel's stain and electron microscopy. *Am J Clin Pathol* 1989; **92**: 329–338.
442. Martinelli R, Pereira LJ, Brito E *et al.* Renal involvement in prolonged *Salmonella* bacteremia: the role of schistosomal glomerulopathy. *Rev Inst Med Trop Sao Paulo* 1992; **34**: 193–198.
443. Bassily S, Farid Z, Barsoum RS *et al.* Renal biopsy in *Schistosoma-Salmonella* associated nephrotic syndrome. *J Trop Med Hyg* 1976; **79**: 256–258.
444. Lambertucci JR, Godoy P, Neves J *et al.* Glomerulonephritis in *Salmonella-Schistosoma mansoni* association. *Am J Trop Med Hyg* 1988; **38**: 97–102.
445. Ross AG, Bartley PB, Sleight AC *et al.* Schistosomiasis. *N Engl J Med* 2002; **346**: 1212–1220.
446. Martinelli R, Pereira LJ, Brito E *et al.* Clinical course of focal segmental glomerulosclerosis associated with hepatosplenic schistosomiasis mansoni. *Nephron* 1995; **69**: 131–134.
447. Sobh MA, Moustafa FE, Sally SM *et al.* A prospective, randomized therapeutic trial for schistosomal specific nephropathy. *Kidney Int* 1989; **36**: 904–907.
448. Abdul-Fattah MM, Yossef SM, Ebraheem ME *et al.* Schistosomal glomerulopathy: a putative role for commonly associated *Salmonella* infection. *J Egypt Soc Parasitol* 1995; **25**: 165–173.
449. Martinelli R, Pereira LJ, Rocha H. The influence of anti-parasitic therapy on the course of the glomerulopathy associated with *Schistosomiasis mansoni*. *Clin Nephrol* 1987; **27**: 229–232.
450. Sobh MA, Moustafa FE, Sally SM *et al.* Characterisation of kidney lesions in early schistosomal-specific nephropathy. *Nephrol Dial Transplant* 1988; **3**: 392–398.
451. Nussenzveig I, De Brito T, Carneiro CR *et al.* Human *Schistosoma mansoni*-associated glomerulopathy in Brazil. *Nephrol Dial Transplant* 2002; **17**: 4–7.
452. Bariety J, Barbier M, Laigre MC *et al.* [Proteinuria and loiasis. Histologic, optic and electronic study of a case]. *Bull Mem Soc Med Hop Paris* 1967; **118**: 1015–1025.

453. Chugh KS, Singhal PC, Tewari SC *et al.* Acute glomerulonephritis associated with filariasis. *Am J Trop Med Hyg* 1978; **27**: 630–631.
454. Date A, Gunasekaran V, Kirubakaran MG *et al.* Acute eosinophilic glomerulonephritis with Bancroftian filariasis. *Postgrad Med J* 1979; **55**: 905–907.
455. Ngu JL, Chatelana F, Leke R *et al.* Nephropathy in Cameroon: evidence for filarial derived immune-complex pathogenesis in some cases. *Clin Nephrol* 1985; **24**: 128–134.
456. Pillay VK, Kirch E, Kurtzman NA. Glomerulopathy associated with filarial loiasis. *JAMA* 1973; **225**: 179.
457. Pakasa NM, Nseka NM, Nyimi LM. Secondary collapsing glomerulopathy associated with Loa loa filariasis. *Am J Kidney Dis* 1997; **30**: 836–839.
458. Ormerod AD, Petersen J, Hussey JK *et al.* Immune complex glomerulonephritis and chronic anaerobic urinary infection—complications of filariasis. *Postgrad Med J* 1983; **59**: 730–733.
459. Hall CL, Stephens L, Peat D *et al.* Nephrotic syndrome due to loiasis following a tropical adventure holiday: a case report and review of the literature. *Clin Nephrol* 2001; **56**: 247–250.
460. Dreyer G, Ottesen EA, Galdino E *et al.* Renal abnormalities in microfilaremic patients with Bancroftian filariasis. *Am J Trop Med Hyg* 1992; **46**: 745–751.
461. Langhammer J, Birk HW, Zahner H. Renal disease in lymphatic filariasis: evidence for tubular and glomerular disorders at various stages of the infection. *Trop Med Int Health* 1997; **2**: 875–884.
462. Cruel T, Arborio M, Schill H *et al.* [Nephropathy and filariasis from Loa loa. Apropos of 1 case of adverse reaction to a dose of ivermectin]. *Bull Soc Pathol Exot* 1997; **90**: 179–181.
463. Ngu JL, Adam M, Leke R *et al.* Proteinuria associated with diethylcarbamazine treatment of onchocerciasis (abstract). *Lancet* 1980; **315**: 710.
464. Abel L, Ioly V, Jeni P *et al.* Apheresis in the management of loiasis with high microfilariaemia and renal disease. *Br Med J (Clin Res Ed)* 1986; **292**: 24.
465. Barsoum RS. Malarial nephropathies. *Nephrol Dial Transplant* 1998; **13**: 1588–1597.
466. Eiam-Ong S. Malarial nephropathy. *Semin Nephrol* 2003; **23**: 21–33.
467. Olowu WA, Adelusola KA, Adefehinti O *et al.* Quartan malaria-associated childhood nephrotic syndrome: now a rare clinical entity in malaria endemic Nigeria. *Nephrol Dial Transplant* 2010; **25**: 794–801.
468. Doe JY, Funk M, Mengel M *et al.* Nephrotic syndrome in African children: lack of evidence for ‘tropical nephrotic syndrome’? *Nephrol Dial Transplant* 2006; **21**: 672–676.
469. Seggie J, Davies PG, Ninin D *et al.* Patterns of glomerulonephritis in Zimbabwe: survey of disease characterised by nephrotic proteinuria. *Q J Med* 1984; **53**: 109–118.
470. Roberts IS, Cook HT, Troyanov S *et al.* The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. *Kidney Int* 2009; **76**: 546–556.
471. Li PK, Ho KK, Szeto CC *et al.* Prognostic indicators of IgA nephropathy in the Chinese—clinical and pathological perspectives. *Nephrol Dial Transplant* 2002; **17**: 64–69.
472. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? *Kidney Int* 2006; **69**: 1455–1458.
473. Go AS, Chertow GM, Fan D *et al.* Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 2004; **351**: 1296–1305.
474. Donadio JV, Bergstralh EJ, Grande JP *et al.* Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. *Nephrol Dial Transplant* 2002; **17**: 1197–1203.
475. Geddes CC, Rauta V, Gronhagen-Riska C *et al.* A tricontinental view of IgA nephropathy. *Nephrol Dial Transplant* 2003; **18**: 1541–1548.
476. Goto M, Wakai K, Kawamura T *et al.* A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. *Nephrol Dial Transplant* 2009; **24**: 3068–3074.
477. Reich HN, Troyanov S, Scholey JW *et al.* Remission of proteinuria improves prognosis in IgA nephropathy. *J Am Soc Nephrol* 2007; **18**: 3177–3183.
478. Coppo R, Peruzzi L, Amore A *et al.* IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. *J Am Soc Nephrol* 2007; **18**: 1880–1888.
479. Cattran DC, Coppo R, Cook HT *et al.* The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. *Kidney Int* 2009; **76**: 534–545.
480. Szeto CC, Lai FM, To KF *et al.* The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. *Am J Med* 2001; **110**: 434–437.
481. Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. *J Nephrol* 2005; **18**: 503–512.
482. Frisch G, Lin J, Rosenstock J *et al.* Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. *Nephrol Dial Transplant* 2005; **20**: 2139–2145.
483. Harmankaya O, Ozturk Y, Basturk T *et al.* Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria. *Int Urol Nephrol* 2002; **33**: 167–171.
484. Bartosik LP, Lajoie G, Sugar L *et al.* Predicting progression in IgA nephropathy. *Am J Kidney Dis* 2001; **38**: 728–735.
485. Kanno Y, Okada H, Saruta T *et al.* Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. *Clin Nephrol* 2000; **54**: 360–365.
486. Jafar TH, Schmid CH, Landa M *et al.* Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. *Ann Intern Med* 2001; **135**: 73–87.
487. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. *Am J Kidney Dis* 2007; **49**: 12–26.
488. Fellin G, Gentile MG, Duca G *et al.* Renal function in IgA nephropathy with established renal failure. *Nephrol Dial Transplant* 1988; **3**: 17–23.
489. Ballardie FW, Roberts IS. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. *J Am Soc Nephrol* 2002; **13**: 142–148.
490. Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by ⁵¹Cr-EDTA clearance. *Kidney Int* 1991; **40**: 1050–1054.
491. D’Amico G, Minetti L, Ponticelli C *et al.* Prognostic indicators in idiopathic IgA mesangial nephropathy. *Q J Med* 1986; **59**: 363–378.
492. Boyce NW, Holdsworth SR, Thomson NM *et al.* Clinicopathological associations in mesangial IgA nephropathy. *Am J Nephrol* 1986; **6**: 246–252.
493. Freese P, Norden G, Nyberg G. Morphologic high-risk factors in IgA nephropathy. *Nephron* 1998; **79**: 420–425.
494. Hogg RJ, Silva FG, Wyatt RJ *et al.* Prognostic indicators in children with IgA nephropathy—report of the Southwest Pediatric Nephrology Study Group. *Pediatr Nephrol* 1994; **8**: 15–20.
495. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. *Nephrol Dial Transplant* 2003; **18**: 1321–1329.
496. Katafuchi R, Oh Y, Hori K *et al.* An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. *Clin Nephrol* 1994; **41**: 191–198.
497. Packham DK, Yan HD, Hewitson TD *et al.* The significance of focal and segmental hyalinosis and sclerosis (FSHS) and nephrotic range proteinuria in IgA nephropathy. *Clin Nephrol* 1996; **46**: 225–229.
498. Hsu CY, McCulloch CE, Iribarren C *et al.* Body mass index and risk for end-stage renal disease. *Ann Intern Med* 2006; **144**: 21–28.
499. Navaneethan SD, Yehner H, Moustarah F *et al.* Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2009; **4**: 1565–1574.
500. Bonnet F, Deprele C, Sassolas A *et al.* Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. *Am J Kidney Dis* 2001; **37**: 720–727.
501. Tanaka M, Tsujii T, Komiya T *et al.* Clinicopathological influence of obesity in IgA nephropathy: comparative study of 74 patients. *Contrib Nephrol* 2007; **157**: 90–93.
502. Coppo R, Troyanov S, Camilla R *et al.* The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. *Kidney Int* 2010; **77**: 921–927.
503. Rauta V, Finne P, Fagerudd J *et al.* Factors associated with progression of IgA nephropathy are related to renal function—a model for estimating risk of progression in mild disease. *Clin Nephrol* 2002; **58**: 85–94.
504. Li PK, Leung CB, Chow KM *et al.* Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. *Am J Kidney Dis* 2006; **47**: 751–760.
505. Praga M, Gutierrez E, Gonzalez E *et al.* Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. *J Am Soc Nephrol* 2003; **14**: 1578–1583.
506. Horita Y, Tadokoro M, Taura K *et al.* Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. *Ren Fail* 2007; **29**: 441–446.

507. Russo D, Pisani A, Balletta MM *et al.* Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. *Am J Kidney Dis* 1999; **33**: 851–856.
508. Yang Y, Ohta K, Shimizu M *et al.* Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. *Clin Nephrol* 2005; **64**: 35–40.
509. Pozzi C, Bolasco PG, Fogazzi GB *et al.* Corticosteroids in IgA nephropathy: a randomised controlled trial. *Lancet* 1999; **353**: 883–887.
510. Manno C, Torres DD, Rossini M *et al.* Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. *Nephrol Dial Transplant* 2009; **24**: 3694–3701.
511. Lv J, Zhang H, Chen Y *et al.* Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. *Am J Kidney Dis* 2009; **53**: 26–32.
512. Pozzi C, Andrulli S, Del Vecchio L *et al.* Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. *J Am Soc Nephrol* 2004; **15**: 157–163.
513. Pozzi C, Locatelli F. Corticosteroids in IgA nephropathy (letter). *Lancet* 1999; **353**: 2159–2160.
514. Manno C, Gesualdo L, D'Altri C *et al.* Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy. *J Nephrol* 2001; **14**: 248–252.
515. Hogg RJ, Lee J, Nardelli N *et al.* Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. *Clin J Am Soc Nephrol* 2006; **1**: 467–474.
516. Katafuchi R, Ikeda K, Mizumasa T *et al.* Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. *Am J Kidney Dis* 2003; **41**: 972–983.
517. Strippoli GF, Maione A, Schena FP *et al.* IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice. *Am J Kidney Dis* 2009; **53**: 5–8.
518. Kobayashi Y, Hiki Y, Kokubo T *et al.* Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. *Nephron* 1996; **72**: 237–242.
519. Eitner F, Ackermann D, Hilgers RD *et al.* Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. *J Nephrol* 2008; **21**: 284–289.
520. Walker RG, Yu SH, Owen JE *et al.* The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. *Clin Nephrol* 1990; **34**: 103–107.
521. Woo KT, Lee GS. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin. *Clin Nephrol* 1991; **35**: 184.
522. Yoshikawa N, Ito H, Sakai T *et al.* A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. *J Am Soc Nephrol* 1999; **10**: 101–109.
523. Pozzi C, Andrulli S, Pani A *et al.* Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. *J Am Soc Nephrol* 2010; **21**: 1783–1790.
524. Yoshikawa N, Honda M, Iijima K *et al.* Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. *Clin J Am Soc Nephrol* 2006; **1**: 511–517.
525. Maes BD, Oyen R, Claes K *et al.* Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. *Kidney Int* 2004; **65**: 1842–1849.
526. Tang S, Leung JC, Chan LY *et al.* Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. *Kidney Int* 2005; **68**: 802–812.
527. Tang SC, Tang AW, Wong SS *et al.* Long-term study of mycophenolate mofetil treatment in IgA nephropathy. *Kidney Int* 2010; **77**: 543–549.
528. Lv J, Zhang H, Cui Z *et al.* Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. *Nephrol Dial Transplant* 2008; **23**: 2868–2872.
529. Donadio Jr JV, Bergstralh EJ, Offord KP *et al.* A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. *N Engl J Med* 1994; **331**: 1194–1199.
530. Donadio Jr JV, Grande JP, Bergstralh EJ *et al.* The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. *J Am Soc Nephrol* 1999; **10**: 1772–1777.
531. Alexopoulos E, Stangou M, Pantzaki A *et al.* Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a “very low dose” regimen. *Ren Fail* 2004; **26**: 453–459.
532. Ferraro PM, Ferraccioli GF, Gambaro G *et al.* Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. *Nephrol Dial Transplant* 2009; **24**: 156–160.
533. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. *Clin Nephrol* 1989; **31**: 128–131.
534. Pettersson EE, Rekola S, Berglund L *et al.* Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. *Clin Nephrol* 1994; **41**: 183–190.
535. Strippoli GF, Manno C, Schena FP. An “evidence-based” survey of therapeutic options for IgA nephropathy: assessment and criticism. *Am J Kidney Dis* 2003; **41**: 1129–1139.
536. Miller III ER, Juraschek SP, Appel LJ *et al.* The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. *Am J Clin Nutr* 2009; **89**: 1937–1945.
537. Hogg RJ, Fitzgibbons L, Atkins C *et al.* Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. *Clin J Am Soc Nephrol* 2006; **1**: 1167–1172.
538. Donadio Jr JV, Larson TS, Bergstralh EJ *et al.* A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. *J Am Soc Nephrol* 2001; **12**: 791–799.
539. Taji Y, Kuwahara T, Shikata S *et al.* Meta-analysis of antiplatelet therapy for IgA nephropathy. *Clin Exp Nephrol* 2006; **10**: 268–273.
540. Hotta O, Miyazaki M, Furuta T *et al.* Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. *Am J Kidney Dis* 2001; **38**: 736–743.
541. Xie Y, Nishi S, Ueno M *et al.* The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. *Kidney Int* 2003; **63**: 1861–1867.
542. Komatsu H, Fujimoto S, Hara S *et al.* Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. *Clin J Am Soc Nephrol* 2008; **3**: 1301–1307.
543. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. *Clin Nephrol* 1999; **51**: 147–152.
544. Kim SM, Moon KC, Oh KH *et al.* Clinicopathologic characteristics of IgA nephropathy with steroid-responsive nephrotic syndrome. *J Korean Med Sci* 2009; **24**(Suppl): S44–S49.
545. Lai KN, Lai FM, Chan KW *et al.* An overlapping syndrome of IgA nephropathy and lipoid nephrosis. *Am J Clin Pathol* 1986; **86**: 716–723.
546. Lai KN, Lai FM, Ho CP *et al.* Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. *Clin Nephrol* 1986; **26**: 174–180.
547. Gutierrez E, Gonzalez E, Hernandez E *et al.* Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. *Clin J Am Soc Nephrol* 2007; **2**: 51–57.
548. Praga M, Gutierrez-Millet V, Navas JJ *et al.* Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy. *Kidney Int* 1985; **28**: 69–74.
549. Bennett WM, Kincaid-Smith P. Macroscopic hematuria in mesangial IgA nephropathy: correlation with glomerular crescents and renal dysfunction. *Kidney Int* 1983; **23**: 393–400.
550. Abe T, Kida H, Yoshimura M *et al.* Participation of extracapillary lesions (ECL) in progression of IgA nephropathy. *Clin Nephrol* 1986; **25**: 37–41.
551. Tang Z, Wu Y, Wang QW *et al.* Idiopathic IgA nephropathy with diffuse crescent formation. *Am J Nephrol* 2002; **22**: 480–486.
552. Pankhurst T, Lepenies J, Nightingale P *et al.* Vasculitic IgA nephropathy: prognosis and outcome. *Nephron Clin Pract* 2009; **112**: c16–c24.
553. Coppo R, Basolo B, Roccatello D *et al.* Plasma exchange in progressive primary IgA nephropathy. *Int J Artif Organs* 1985; **8**(Suppl 2): 55–58.
554. Saulsbury FT. Clinical update: Henoch-Schonlein purpura. *Lancet* 2007; **369**: 976–978.
555. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. *Arch Dis Child* 2005; **90**: 916–920.
556. Saulsbury FT. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. *Medicine (Baltimore)* 1999; **78**: 395–409.
557. Shin JI, Park JM, Shin YH *et al.* Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schonlein purpura. *Scand J Rheumatol* 2006; **35**: 56–60.

558. Goldstein AR, White RH, Akuse R *et al.* Long-term follow-up of childhood Henoch-Schonlein nephritis. *Lancet* 1992; **339**: 280-282.
559. Edstrom Halling S, Soderberg MP, Berg UB. Predictors of outcome in Henoch-Schonlein nephritis. *Pediatr Nephrol* 2010; **25**: 1101-1108.
560. Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. *Lancet* 2002; **360**: 666-670.
561. Zaffanello M, Fanos V. Treatment-based literature of Henoch-Schonlein purpura nephritis in childhood. *Pediatr Nephrol* 2009; **24**: 1901-1911.
562. Ronkainen J, Koskimies O, Ala-Houhala M *et al.* Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. *J Pediatr* 2006; **149**: 241-247.
563. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. *Pediatr Nephrol* 1998; **12**: 238-243.
564. Foster BJ, Bernard C, Drummond KN *et al.* Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. *J Pediatr* 2000; **136**: 370-375.
565. Tarshish P, Bernstein J, Edelmann Jr CM. Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide. *Pediatr Nephrol* 2004; **19**: 51-56.
566. Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. *Nephrol Dial Transplant* 2004; **19**: 858-864.
567. Ronkainen J, Ala-Houhala M, Antikainen M *et al.* Cyclosporine A (CyA) versus MP pulses (MP) in the treatment of severe Henoch-Schonlein Nephritis (HSN) (abstract). *Pediatr Nephrol* 2006; **21**: 1531.
568. Jauhola O, Ronkainen J, Ala-Houhala M *et al.* Cyclosporine A (CyA) versus MP pulses in severe Henoch-Schonlein Nephritis (HSN): Outcome after 2 year follow up (abstract). *Pediatr Nephrol* 2008; **23**: 1584.
569. Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. *Clin Nephrol* 1998; **49**: 9-14.
570. Flynn JT, Smoyer WE, Bunchman TE *et al.* Treatment of Henoch-Schonlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. *Am J Nephrol* 2001; **21**: 128-133.
571. Ronkainen J, Autio-Harmainen H, Nuutinen M. Cyclosporin A for the treatment of severe Henoch-Schonlein glomerulonephritis. *Pediatr Nephrol* 2003; **18**: 1138-1142.
572. Shin JI, Park JM, Shin YH *et al.* Cyclosporin A therapy for severe Henoch-Schonlein nephritis with nephrotic syndrome. *Pediatr Nephrol* 2005; **20**: 1093-1097.
573. Kawasaki Y, Suzuki J, Murai M *et al.* Plasmapheresis therapy for rapidly progressive Henoch-Schonlein nephritis. *Pediatr Nephrol* 2004; **19**: 920-923.
574. Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. *Pediatr Nephrol* 2007; **22**: 1167-1171.
575. Fuentes Y, Valverde S, Valesquez-Jones L *et al.* Comparison of azathioprine vs mofetil mycophenolate for Henoch-Schonlein nephritis treatment (abstract). *Pediatr Nephrol* 2010; **25**: 1802.
576. Chartapisak W, Opastiraku S, Willis NS *et al.* Prevention and treatment of renal disease in Henoch-Schonlein purpura: a systematic review. *Arch Dis Child* 2009; **94**: 132-137.
577. Chartapisak W, Opastiraku S, Hodson EM *et al.* Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura (HSP). *Cochrane Database Syst Rev* 2009; CD005128.
578. Dudley J, Smith G, Llewellyn-Edwards A *et al.* Randomised placebo controlled trial to assess the role of early prednisolone on the development and progression of Henoch-Schonlein Purpura Nephritis (abstract). *Pediatr Nephrol* 2007; **22**: 1457.
579. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V *et al.* Henoch-Schonlein purpura in adulthood and childhood: two different expressions of the same syndrome. *Arthritis Rheum* 1997; **40**: 859-864.
580. Coppo R, Andrulli S, Amore A *et al.* Predictors of outcome in Henoch-Schonlein nephritis in children and adults. *Am J Kidney Dis* 2006; **47**: 993-1003.
581. Shrestha S, Sumingan N, Tan J *et al.* Henoch Schonlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. *QJM* 2006; **99**: 253-265.
582. Rauta V, Tornroth T, Gronhagen-Riska C. Henoch-Schoenlein nephritis adults-clinical features and outcomes in Finnish patients. *Clin Nephrol* 2002; **58**: 1-8.
583. Hung SP, Yang YH, Lin YT *et al.* Clinical manifestations and outcomes of Henoch-Schonlein purpura: comparison between adults and children. *Pediatr Neonatol* 2009; **50**: 162-168.
584. Pillebout E, Thervet E, Hill G *et al.* Henoch-Schonlein Purpura in adults: outcome and prognostic factors. *J Am Soc Nephrol* 2002; **13**: 1271-1278.
585. Pillebout E, Alberti C, Guillevin L *et al.* Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein Purpura. *Kidney Int* 2010; **78**: 495-502.
586. Campbell Jr R, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. *Arthritis Rheum* 2008; **59**: 458-464.
587. Danila MI, Pons-Estel GJ, Zhang J *et al.* Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. *Rheumatology (Oxford)* 2009; **48**: 542-545.
588. Font J, Ramos-Casals M, Cervera R *et al.* Cardiovascular risk factors and the long-term outcome of lupus nephritis. *QJM* 2001; **94**: 19-26.
589. Al Arfaj AS, Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. *Lupus* 2009; **18**: 465-473.
590. Bastian HM, Roseman JM, McGwin Jr G *et al.* Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. *Lupus* 2002; **11**: 152-160.
591. Seligman VA, Lum RF, Olson JL *et al.* Demographic differences in the development of lupus nephritis: a retrospective analysis. *Am J Med* 2002; **112**: 726-729.
592. Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. *J Rheumatol* 2009; **36**: 63-67.
593. Adler M, Chambers S, Edwards C *et al.* An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. *Rheumatology (Oxford)* 2006; **45**: 1144-1147.
594. Al Arfaj AS, Khalil N, Al Saleh S. Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia. *Rheumatol Int* 2009; **29**: 1057-1067.
595. Gonzalez-Crespo MR, Lopez-Fernandez JJ, Usera G *et al.* Outcome of silent lupus nephritis. *Semin Arthritis Rheum* 1996; **26**: 468-476.
596. Valente de Almeida R, Rocha de Carvalho JG, de Azevedo VF *et al.* Microalbuminuria and renal morphology in the evaluation of subclinical lupus nephritis. *Clin Nephrol* 1999; **52**: 218-229.
597. Zabaleta-Lanz ME, Munoz LE, Tapanes FJ *et al.* Further description of early clinically silent lupus nephritis. *Lupus* 2006; **15**: 845-851.
598. Kraft SW, Schwartz MM, Korbet SM *et al.* Glomerular podocytopeny in patients with systemic lupus erythematosus. *J Am Soc Nephrol* 2005; **16**: 175-179.
599. Austin III HA, Klippel JH, Balow JE *et al.* Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. *N Engl J Med* 1986; **314**: 614-619.
600. Boumpas DT, Austin III HA, Vaughn EM *et al.* Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. *Lancet* 1992; **340**: 741-745.
601. Donadio Jr JV, Holley KE, Ferguson RH *et al.* Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. *N Engl J Med* 1978; **299**: 1151-1155.
602. Gourley MF, Austin III HA, Scott D *et al.* Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. *Ann Intern Med* 1996; **125**: 549-557.
603. Houssiau FA, Vasconcelos C, D'Cruz D *et al.* The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. *Ann Rheum Dis* 2010; **69**: 61-64.
604. Houssiau FA, Vasconcelos C, D'Cruz D *et al.* Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. *Arthritis Rheum* 2002; **46**: 2121-2131.
605. McKinley A, Park E, Spetie D *et al.* Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. *Clin J Am Soc Nephrol* 2009; **4**: 1754-1760.
606. Moroni G, Doria A, Mosca M *et al.* A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. *Clin J Am Soc Nephrol* 2006; **1**: 925-932.
607. Chan TM, Tse KC, Tang CS *et al.* Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. *Lupus* 2005; **14**: 265-272.

608. Mok CC, Ho CT, Chan KW *et al.* Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. *Arthritis Rheum* 2002; **46**: 1003–1013.
609. Mok CC, Ho CT, Siu YP *et al.* Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. *Am J Kidney Dis* 2001; **38**: 256–264.
610. Moroni G, Quaglini S, Gallelli B *et al.* The long-term outcome of 93 patients with proliferative lupus nephritis. *Nephrol Dial Transplant* 2007; **22**: 2531–2539.
611. Chan TM, Li FK, Tang CS *et al.* Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. *N Engl J Med* 2000; **343**: 1156–1162.
612. Chan TM, Tse KC, Tang CS *et al.* Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. *J Am Soc Nephrol* 2005; **16**: 1076–1084.
613. Appel GB, Contreras G, Dooley MA *et al.* Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. *J Am Soc Nephrol* 2009; **20**: 1103–1112.
614. Traitanon O, Avihingsanon Y, Kittikovit V *et al.* Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. *Lupus* 2008; **17**: 744–751.
615. Grootsholten C, Ligtenberg G, Hagen EC *et al.* Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. *Kidney Int* 2006; **70**: 732–742.
616. Grootsholten C, Bajema IM, Florquin S *et al.* Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. *Arthritis Rheum* 2007; **56**: 924–937.
617. Zavada J, Pesickova S, Rysava R *et al.* Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. *Lupus* 2010; **19**: 1281–1289.
618. Bao H, Liu ZH, Xie HL *et al.* Successful treatment of class V+IV lupus nephritis with multitarget therapy. *J Am Soc Nephrol* 2008; **19**: 2001–2010.
619. Balow JE, Austin III HA, Muenz LR *et al.* Effect of treatment on the evolution of renal abnormalities in lupus nephritis. *N Engl J Med* 1984; **311**: 491–495.
620. Haubitz M, Bohnenstengel F, Brunkhorst R *et al.* Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. *Kidney Int* 2002; **61**: 1495–1501.
621. Pendse S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosuppression. *Am J Kidney Dis* 2004; **43**: 772–781.
622. Somers EC, Marder W, Christman GM *et al.* Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. *Arthritis Rheum* 2005; **52**: 2761–2767.
623. Ginzler EM, Dooley MA, Aranow C *et al.* Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *N Engl J Med* 2005; **353**: 2219–2228.
624. Hu W, Liu Z, Chen H *et al.* Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. *Chin Med J (Engl)* 2002; **115**: 705–709.
625. Ong LM, Hooi LS, Lim TO *et al.* Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. *Nephrology (Carlton)* 2005; **10**: 504–510.
626. El-Shafey EM, Abdou SH, Shareef MM. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? *Clin Exp Nephrol* 2010; **14**: 214–221.
627. Korbet SM, Schwartz MM, Evans J *et al.* Severe lupus nephritis: racial differences in presentation and outcome. *J Am Soc Nephrol* 2007; **18**: 244–254.
628. Rovin BH, Appel GB, Furie RA *et al.* Efficacy and safety of rituximab (RTX) in subjects with proliferative lupus nephritis (LN): Results from the randomized, double-blind, phase III LUNAR study (abstract). *J Am Soc Nephrol* 2009; **20**: 77A.
629. Gunnarsson I, Sundelin B, Jonsdottir T *et al.* Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. *Arthritis Rheum* 2007; **56**: 1263–1272.
630. Karim MY, Pisoni CN, Khamashta MA. Update on immunotherapy for systemic lupus erythematosus—what's hot and what's not!. *Rheumatology (Oxford)* 2009; **48**: 332–341.
631. Li EK, Tam LS, Zhu TY *et al.* Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? *Rheumatology (Oxford)* 2009; **48**: 892–898.
632. Lu TY, Ng KP, Cambridge G *et al.* A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. *Arthritis Rheum* 2009; **61**: 482–487.
633. Ramos-Casals M, Soto MJ, Cuadrado MJ *et al.* Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. *Lupus* 2009; **18**: 767–776.
634. Sousa E, Isenberg D. Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. *Best Pract Res Clin Rheumatol* 2009; **23**: 563–574.
635. Tieng AT, Peeva E. B-cell-directed therapies in systemic lupus erythematosus. *Semin Arthritis Rheum* 2008; **38**: 218–227.
636. Cameron JS, Turner DR, Ogg CS *et al.* Systemic lupus with nephritis: a long-term study. *Q J Med* 1979; **48**: 1–24.
637. Dooley MA, Jayne D, Ginzler EM *et al.* Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. *N Engl J Med* 2011; **365**: 1886–1895.
638. Contreras G, Pardo V, Leclercq B *et al.* Sequential therapies for proliferative lupus nephritis. *N Engl J Med* 2004; **350**: 971–980.
639. Houssiau FA, D'Cruz D, Sangle S *et al.* Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. *Ann Rheum Dis* 2010; **69**: 2083–2089.
640. Griffiths B, Emery P, Ryan V *et al.* The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. *Rheumatology (Oxford)* 2010; **49**: 723–732.
641. Gunnarsson I, Sundelin B, Heimburger M *et al.* Repeated renal biopsy in proliferative lupus nephritis—predictive role of serum C1q and albuminuria. *J Rheumatol* 2002; **29**: 693–699.
642. Hill GS, Delahousse M, Nochy D *et al.* Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. *Kidney Int* 2001; **59**: 304–316.
643. Ioannidis JP, Boki KA, Katsorida ME *et al.* Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. *Kidney Int* 2000; **57**: 258–264.
644. Moroni G, Pasquali S, Quaglini S *et al.* Clinical and prognostic value of serial renal biopsies in lupus nephritis. *Am J Kidney Dis* 1999; **34**: 530–539.
645. Chen YE, Korbet SM, Katz RS *et al.* Value of a complete or partial remission in severe lupus nephritis. *Clin J Am Soc Nephrol* 2008; **3**: 46–53.
646. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. *Am J Kidney Dis* 1992; **19**: 473–479.
647. Barr RG, Seliger S, Appel GB *et al.* Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. *Nephrol Dial Transplant* 2003; **18**: 2039–2046.
648. Contreras G, Pardo V, Cely C *et al.* Factors associated with poor outcomes in patients with lupus nephritis. *Lupus* 2005; **14**: 890–895.
649. Gibson KL, Gipson DS, Massengill SA *et al.* Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. *Clin J Am Soc Nephrol* 2009; **4**: 1962–1967.
650. Rovin BH, Zhang X. Biomarkers for lupus nephritis: the quest continues. *Clin J Am Soc Nephrol* 2009; **4**: 1858–1865.
651. Hebert LA, Wilmer WA, Falkenhain ME *et al.* Renoprotection: one or many therapies? *Kidney Int* 2001; **59**: 1211–1226.
652. Wilmer WA, Rovin BH, Hebert CJ *et al.* Management of glomerular proteinuria: a commentary. *J Am Soc Nephrol* 2003; **14**: 3217–3232.
653. Coremans IE, Spronk PE, Bootsma H *et al.* Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. *Am J Kidney Dis* 1995; **26**: 595–601.
654. Esdaile JM, Abrahamowicz M, Joseph L *et al.* Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. *Arthritis Rheum* 1996; **39**: 370–378.
655. Esdaile JM, Joseph L, Abrahamowicz M *et al.* Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? *J Rheumatol* 1996; **23**: 1891–1896.

656. Ho A, Barr SG, Magder LS *et al.* A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. *Arthritis Rheum* 2001; **44**: 2350–2357.
657. Ho A, Magder LS, Barr SG *et al.* Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. *Arthritis Rheum* 2001; **44**: 2342–2349.
658. Moroni G, Radice A, Giammarresi G *et al.* Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. *Ann Rheum Dis* 2009; **68**: 234–237.
659. Rovin BH, Birmingham DJ, Nagaraja HN *et al.* Biomarker discovery in human SLE nephritis. *Bull NYU Hosp Jt Dis* 2007; **65**: 187–193.
660. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. *Ann Intern Med* 1997; **127**: 337–345.
661. Mercadal L, Montcel ST, Nochy D *et al.* Factors affecting outcome and prognosis in membranous lupus nephropathy. *Nephrol Dial Transplant* 2002; **17**: 1771–1778.
662. Mok CC. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. *Nat Rev Nephrol* 2009; **5**: 212–220.
663. Mok CC, Ying KY, Yim CW *et al.* Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. *Lupus* 2009; **18**: 1091–1095.
664. Pasquali S, Banfi G, Zucchelli A *et al.* Lupus membranous nephropathy: long-term outcome. *Clin Nephrol* 1993; **39**: 175–182.
665. Sloan RP, Schwartz MM, Korbet SM *et al.* Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. *J Am Soc Nephrol* 1996; **7**: 299–305.
666. Donadio Jr JV, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. *Medicine (Baltimore)* 1977; **56**: 527–536.
667. Gonzalez-Dettoni H, Tron F. Membranous glomerulopathy in systemic lupus erythematosus. *Adv Nephrol Necker Hosp* 1985; **14**: 347–364.
668. Ordonez JD, Hiatt RA, Killebrew EJ *et al.* The increased risk of coronary heart disease associated with nephrotic syndrome. *Kidney Int* 1993; **44**: 638–642.
669. Mok CC, Ying KY, Lau CS *et al.* Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. *Am J Kidney Dis* 2004; **43**: 269–276.
670. Austin III HA, Illei GG, Braun MJ *et al.* Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. *J Am Soc Nephrol* 2009; **20**: 901–911.
671. Kasitanon N, Petri M, Haas M *et al.* Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. *Lupus* 2008; **17**: 40–45.
672. Spetie DN, Tang Y, Rovin BH *et al.* Mycophenolate therapy of SLE membranous nephropathy. *Kidney Int* 2004; **66**: 2411–2415.
673. Szeto CC, Kwan BC, Lai FM *et al.* Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. *Rheumatology (Oxford)* 2008; **47**: 1678–1681.
674. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P *et al.* Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis* 2010; **69**: 20–28.
675. Tsakonas E, Joseph L, Esdaile JM *et al.* A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. *Lupus* 1998; **7**: 80–85.
676. Siso A, Ramos-Casals M, Bove A *et al.* Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. *Lupus* 2008; **17**: 281–288.
677. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. *Ann Rheum Dis* 2009; **68**: 238–241.
678. Pons-Estel GJ, Alarcon GS, McGwin Jr G *et al.* Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. *Arthritis Rheum* 2009; **61**: 830–839.
679. Illei GG, Takada K, Parkin D *et al.* Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. *Arthritis Rheum* 2002; **46**: 995–1002.
680. Esdaile JM, Joseph L, MacKenzie T *et al.* The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. *Semin Arthritis Rheum* 1993; **23**: 135–148.
681. Daleboudt GMN, Bajema IM, Goemaere NNT *et al.* The clinical relevance of a repeat biopsy in lupus nephritis flares. *Nephrol Dial Transplant* 2009; **24**: 3712–3717.
682. Birmingham DJ, Nagaraja HN, Rovin BH *et al.* Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A -1019 G allele. *Arthritis Rheum* 2006; **54**: 3291–3299.
683. Clough JD, Lewis EJ, Lachin JM. Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. *Prog Clin Biol Res* 1990; **337**: 301–307.
684. Linnik MD, Hu JZ, Heilbrunn KR *et al.* Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. *Arthritis Rheum* 2005; **52**: 1129–1137.
685. Rovin BH, Song H, Birmingham DJ *et al.* Urine chemokines as biomarkers of human systemic lupus erythematosus activity. *J Am Soc Nephrol* 2005; **16**: 467–473.
686. Rovin BH, Nadasdy G, Nuovo GJ *et al.* Expression of adiponectin and its receptors in the kidney during SLE nephritis (abstract). *J Am Soc Nephrol* 2006; **17**: 256A.
687. Rovin BH, Stillman IE. Kidney. In: Lahita RG, Tsokos GT, Buyon JP, Koike T (eds). *Systemic Lupus Erythematosus*, 5th edn. Elsevier: Waltham, MA, 2011, pp 769–814.
688. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M *et al.* Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. *Lupus* 2010; **19**: 213–219.
689. Rauova L, Lukac J, Levy Y *et al.* High-dose intravenous immunoglobulins for lupus nephritis—a salvage immunomodulation. *Lupus* 2001; **10**: 209–213.
690. Ogawa H, Kameda H, Amano K *et al.* Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. *Lupus* 2010; **19**: 162–169.
691. Ogawa H, Kameda H, Nagasawa H *et al.* Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. *Mod Rheumatol* 2007; **17**: 92–97.
692. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. *Mod Rheumatol* 2009; **19**: 606–615.
693. Daugas E, Nochy D, Huong DL *et al.* Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. *J Am Soc Nephrol* 2002; **13**: 42–52.
694. Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. *Clin Rev Allergy Immunol* 2009; **36**: 131–140.
695. Tektonidou MG, Sotsiou F, Moutsopoulos HM. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. *J Rheumatol* 2008; **35**: 1983–1988.
696. Crowther MA, Ginsberg JS, Julian J *et al.* A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. *N Engl J Med* 2003; **349**: 1133–1138.
697. Finazzi G, Marchioli R, Brancaccio V *et al.* A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). *J Thromb Haemost* 2005; **3**: 848–853.
698. Kwok SK, Ju JH, Cho CS *et al.* Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. *Lupus* 2009; **18**: 16–21.
699. Tandon A, Ibanez D, Gladman DD *et al.* The effect of pregnancy on lupus nephritis. *Arthritis Rheum* 2004; **50**: 3941–3946.
700. Carvalheiras G, Vita P, Marta S *et al.* Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. *Clin Rev Allergy Immunol* 2010; **38**: 302–306.
701. Imbasciati E, Tincani A, Gregorini G *et al.* Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. *Nephrol Dial Transplant* 2009; **24**: 519–525.
702. Wagner SJ, Craici I, Reed D *et al.* Maternal and foetal outcomes in pregnant patients with active lupus nephritis. *Lupus* 2009; **18**: 342–347.
703. Levy RA, Vilela VS, Cataldo MJ *et al.* Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. *Lupus* 2001; **10**: 401–404.

704. Hogan SL, Nachman PH, Wilkman AS *et al.* Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. *J Am Soc Nephrol* 1996; **7**: 23–32.
705. de Groot K, Harper L, Jayne DR *et al.* Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 2009; **150**: 670–680.
706. Hogan SL, Falk RJ, Chin H *et al.* Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. *Ann Intern Med* 2005; **143**: 621–631.
707. Jayne DR, Gaskin G, Rasmussen N *et al.* Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol* 2007; **18**: 2180–2188.
708. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R *et al.* Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. *J Am Soc Nephrol* 2007; **18**: 2189–2197.
709. Nachman PH, Hogan SL, Jennette JC *et al.* Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. *J Am Soc Nephrol* 1996; **7**: 33–39.
710. Walters GD, Willis NS, Craig JC. Interventions for renal vasculitis in adults. A systematic review. *BMC Nephrol* 2010; **11**: 12.
711. Jayne D, Rasmussen N, Andrassy K *et al.* A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003; **349**: 36–44.
712. Guillevin L, Cohen P, Mahr A *et al.* Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. *Arthritis Rheum* 2003; **49**: 93–100.
713. Jones RB, Tervaert JW, Hauser T *et al.* Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010; **363**: 211–220.
714. Stone JH, Merkel PA, Spiera R *et al.* Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 2010; **363**: 221–232.
715. Cole E, Cattran D, Magil A *et al.* A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. *Am J Kidney Dis* 1992; **20**: 261–269.
716. Lauque D, Cadranet J, Lazor R *et al.* Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O" P). *Medicine (Baltimore)* 2000; **79**: 222–233.
717. Klemmer PJ, Chalermkulrat W, Reif MS *et al.* Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. *Am J Kidney Dis* 2003; **42**: 1149–1153.
718. Holguin F, Ramadan B, Gal AA *et al.* Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. *Am J Med Sci* 2008; **336**: 321–326.
719. Rutgers A, Slot M, van Paassen P *et al.* Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. *Am J Kidney Dis* 2005; **46**: 253–262.
720. Silva F, Specks U, Kalra S *et al.* Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement—a prospective, open-label pilot trial. *Clin J Am Soc Nephrol* 2010; **5**: 445–453.
721. Stassen PM, Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. *Ann Rheum Dis* 2007; **66**: 798–802.
722. Hu W, Liu C, Xie H *et al.* Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. *Nephrol Dial Transplant* 2008; **23**: 1307–1312.
723. Sanders JS, Huitma MG, Kallenberg CG *et al.* Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. *Rheumatology (Oxford)* 2006; **45**: 724–729.
724. Hiemstra TF, Walsh M, Mahr A *et al.* Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. *JAMA* 2010; **304**: 2381–2388.
725. Stegeman CA, Tervaert JW, de Jong PE *et al.* Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. *N Engl J Med* 1996; **335**: 16–20.
726. Pagnoux C, Mahr A, Hamidou MA *et al.* Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. *N Engl J Med* 2008; **359**: 2790–2803.
727. Lionaki S, Hogan SL, Jennette CE *et al.* The clinical course of ANCA small-vessel vasculitis on chronic dialysis. *Kidney Int* 2009; **76**: 644–651.
728. Weidanz F, Day CJ, Hewins P *et al.* Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. *Am J Kidney Dis* 2007; **50**: 36–46.
729. Martinez V, Cohen P, Pagnoux C *et al.* Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. *Arthritis Rheum* 2008; **58**: 308–317.
730. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. *Am J Kidney Dis* 2008; **51**: 491–503.
731. Jayne DR, Chapel H, Adu D *et al.* Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. *QJM* 2000; **93**: 433–439.
732. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. *J Intern Med* 2005; **257**: 540–548.
733. Keogh KA, Wylam ME, Stone JH *et al.* Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2005; **52**: 262–268.
734. Stasi R, Stipa E, Del Poeta G *et al.* Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. *Rheumatology (Oxford)* 2006; **45**: 1432–1436.
735. Finkelman JD, Merkel PA, Schroeder D *et al.* Anti-proteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. *Ann Intern Med* 2007; **147**: 611–619.
736. Nowack R, Grab I, Flores-Suarez LF *et al.* ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. *Nephrol Dial Transplant* 2001; **16**: 1631–1637.
737. Gera M, Griffin MD, Specks U *et al.* Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosuppression. *Kidney Int* 2007; **71**: 1296–1301.
738. Nachman PH, Segelmark M, Westman K *et al.* Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. *Kidney Int* 1999; **56**: 1544–1550.
739. Little MA, Hassan B, Jacques S *et al.* Renal transplantation in systemic vasculitis: when is it safe? *Nephrol Dial Transplant* 2009; **24**: 3219–3225.
740. Levy JB, Turner AN, Rees AJ *et al.* Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. *Ann Intern Med* 2001; **134**: 1033–1042.
741. Johnson JP, Moore Jr J, Austin III HA *et al.* Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. *Medicine (Baltimore)* 1985; **64**: 219–227.
742. Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. *Kidney Int Suppl* 1999; **70**: S33–S40.
743. Cui Z, Zhao MH, Xin G *et al.* Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. *Nephron Clin Pract* 2005; **99**: c49–c55.
744. Levy JB, Hammad T, Coulthart A *et al.* Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. *Kidney Int* 2004; **66**: 1535–1540.
745. Li FK, Tse KC, Lam MF *et al.* Incidence and outcome of antiglomerular basement membrane disease in Chinese. *Nephrology (Carlton)* 2004; **9**: 100–104.
746. Lindic J, Vizjak A, Ferluga D *et al.* Clinical outcome of patients with coexistent antineutrophil cytoplasmic antibodies and antibodies against glomerular basement membrane. *Ther Apher Dial* 2009; **13**: 278–281.
747. Segelmark M, Hellmark T, Wieslander J. The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. *Nephron Clin Pract* 2003; **94**: c59–c68.
748. Hirayama K, Yamagata K, Kobayashi M *et al.* Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. *Clin Exp Nephrol* 2008; **12**: 339–347.
749. Shah MK, Huggins SY. Characteristics and outcomes of patients with Goodpasture's syndrome. *South Med J* 2002; **95**: 1411–1418.
750. Stegmayr BG, Almroth G, Berlin G *et al.* Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic

- glomerulonephritis. A Swedish multi-center study. *Int J Artif Organs* 1999; **22**: 81–87.
751. Proskey AJ, Weatherbee L, Easterling RE *et al*. Goodpasture's syndrome. A report of five cases and review of the literature. *Am J Med* 1970; **48**: 162–173.
752. Levy JB, Lachmann RH, Pusey CD. Recurrent Goodpasture's disease. *Am J Kidney Dis* 1996; **27**: 573–578.
753. Adler S, Bruns FJ, Fraley DS *et al*. Rapid progressive glomerulonephritis: relapse after prolonged remission. *Arch Intern Med* 1981; **141**: 852–854.
754. Hind CR, Bowman C, Winearls CG *et al*. Recurrence of circulating anti-glomerular basement membrane antibody three years after immunosuppressive treatment and plasma exchange. *Clin Nephrol* 1984; **21**: 244–246.
755. Klasa RJ, Abboud RT, Ballon HS *et al*. Goodpasture's syndrome: recurrence after a five-year remission. Case report and review of the literature. *Am J Med* 1988; **84**: 751–755.
756. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. *Am J Transplant* 2006; **6**: 2535–2542.
757. Joshi K, Nada R, Minz M *et al*. Recurrent glomerulopathy in the renal allograft. *Transplant Proc* 2007; **39**: 734–736.
758. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. *Ann Intern Med* 1997; **127**: 380–387.
759. Atkins D, Best D, Briss PA *et al*. Grading quality of evidence and strength of recommendations. *BMJ* 2004; **328**: 1490.
760. Guyatt GH, Oxman AD, Kunz R *et al*. Going from evidence to recommendations. *BMJ* 2008; **336**: 1049–1051.
761. Uhlig K, Macleod A, Craig J *et al*. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006; **70**: 2058–2065.
762. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. *Qual Saf Health Care* 2003; **12**: 18–23.
763. Shiffman RN, Shekelle P, Overhage JM *et al*. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. *Ann Intern Med* 2003; **139**: 493–498.
764. *Finding what Works in Health Care: Standards for Systematic Reviews*. IOM (Institute of Medicine): Washington, DC 2011.
765. *Clinical Practice Guidelines we can Trust*. IOM (Institute of Medicine): Washington, DC 2011.